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Abstract: Histone deacetylases (HDACs) are master regulators of chromatin remodeling, acting as
epigenetic regulators of gene expression. In the last decade, inhibition of HDACs has become
a target for specific epigenetic modifications related to cancer development. Overexpression of
HDAC has been observed in several hematologic malignancies. Therefore, the observation that
HDACs might play a role in various hematologic malignancies has brought to the development
of HDAC inhibitors as potential antitumor agents. Recently, the class IIb, HDAC6, has emerged
as one potential selective HDACi. This isoenzyme represents an important pharmacological target
for selective inhibition. Its selectivity may reduce the toxicity related to the off-target effects of
pan-HDAC inhibitors. HDAC6 has also been studied in cancer especially for its ability to coordinate
a variety of cellular processes that are important for cancer pathogenesis. HDAC6 has been reported
to be overexpressed in lymphoid cells and its inhibition has demonstrated activity in preclinical and
clinical study of lymphoproliferative disease. Various studies of HDAC6 inhibitors alone and in
combination with other agents provide strong scientific rationale for the evaluation of these new
agents in the clinical setting of hematological malignancies. In this review, we describe the HDACs,
their inhibitors, and the recent advances of HDAC6 inhibitors, their mechanisms of action and role in
lymphoproliferative disorders.
Keywords: histone deacetylase; histone deacetylase inhibitor; HDAC6; HDAC6 inhibitors;
lymphoproliferative disease; epigenetic
1. Introduction
For a long time, cancer has been considered the result of a series of DNA mutations that induce
the activation of oncogenes and the inactivation of tumor suppressor genes.
In addition to the modifications of the gene sequence, the epigenetic alterations of DNA also play
a crucial role in the development of the tumor, deregulating gene transcription and contributing to
the neoplastic process. Tumorigenesis is therefore the result of both genetic and epigenetic events [1].
“Epigenetic” is defined as biochemical changes of DNA chromatin that control the tertiary DNA
structure resulting in modification of DNA gene expression that are not mediated by modifications in
the primary nucleotide sequence. Epigenetic changes modify chromatin structure and the accessibility
of DNA, thus regulating gene expression without altering the primary DNA sequence. It has been
linked to the development of malignant phenotype and tumor progression, as a possible result of
anomalous silencing of multiple tumor suppressor genes [2–4]. This process includes DNA methylation,
phosphorylation, and histone acetylation that alter DNA accessibility and chromatin structure without
modifications in the DNA sequence. Histone acetylation and deacetylation are regulatory mechanisms
that play an important role in the control of gene transcription, affecting the interaction between DNA
and histones. Histone acetylation induces activation of gene transcription, whereas deacetylation
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is associated with transcriptional repression. The two processes are catalyzed by two specific
enzymes, histone acetyltransferases (HAT), and histone deacetylases (HDACs) [5]. HAT acetylate
either arginine-(R) or lysine-(K) residues. Acetylated chromatin has a relaxed structure that promote
gene transcription. HDACs are regulators of gene expression that enzymatically remove the acetyl
group from arginine and lysine residues in histones [6]. HDACs stabilize and condense chromosome,
making it less available for transcription factors. Interruption of HAT and HDAC activities has been
related with the development of a variety of human cancers including hematological malignancies [7].
Interference with HDACs activity may influence both gene expression and other cellular processes
including cell apoptosis, growth arrest, differentiation, and inhibition of angiogenesis.
HAT and HDAC not only affect histones but modify a large variety of non-histone proteins whose
activity depends on their acetylation status, such as transcription factors, signal transduction mediators,
structural proteins, and inflammation mediators [8,9]. The non-histone proteins, regulated by HDAC,
work in nucleus, cytoplasm, and mitochondria and are involved in different pathways associated in
cancer including lymphoproliferative disease [8,9].
In this review, we describe the HDACs, their inhibitors and in particular the recent advances
of the selective histone deacetylases six inhibitors, their mechanisms of action and their role in
lymphoproliferative disorders.
2. HDAC Classification and Their Physiological Roles
2.1. HDAC Classification and Their Physiological Roles in Lymphoid Lineage
HDACs differ in their structure, substrate specificity, enzymatic mechanism, subcellular
localization, and tissue-specific expression. HDACs comprise a family of 18 enzymes, grouped
in four classes, that play diverse roles in mammalian cell homeostasis and in tumor growth. The four
classes are based on their sequence homology to their yeast orthologues: (1) Class-I HDACs includes
HDACs 1, 2, 3, and 8, they are widely expressed in the tissues, located in the nucleus, and are
involved in cell proliferation and survival; (2) class II family HDACs seem to have tissue-specific
roles depending on the phosphorylation status. They can shuttle between the cytosol and nucleus.
They are divided into two subgroups, class-IIa that comprises HDACs 4, 5, 7, and 9 and class-IIb,
located in the cytoplasm and nucleus; includes HDACs 6 and 10. HDAC6 alone is specific for alpha
tubulin, an important protein required for cell mitosis and movement; (3) class III, known as sirtuins
1–7, require nicotinamide adenine dinucleotide (NAD+) as a coenzyme for their activity; (4) class IV,
which exhibits features of class I and II includes only HDAC 11 localized in the nucleus and has been
implicated in the regulation of interleukin-10 expression [10] (Table 1).
HDACs are involved in diverse pathways and functions in the cells; they often occur in complexes
and are involved in a network of interactions. In physiologic condition, all HDACs, with the exception
of HDAC8, mediate their functions through complex macromolecular formation that very often include
more than one HDAC and corepressor proteins such as Sin3A, N-Cor (nuclear receptor co-repressor),
and SMRT (silencing mediator of retinoid and thyroid receptors).
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Table 1. Histone deacetylases (HDACs) classification, their localization and biological functions.
Class Members Cellular Localization Biological Functions
I
HDAC1 Nucleus
Proliferation control, apoptosis; p21 and p27 CDK (cyclin-dependent kinase) inhibitor repression; Represses
transcription; Binds to transcription factors; Resistance to chemotherapy; Suppresses cytokine production in activated
T cells and during T effector cell differentiation
HDAC2 Nucleus Negatively regulates transcription by being recruited to DNA as a corepressor; Proliferation control; Apoptosis
HDAC3 Nucleus Proliferation; Differentiation, represses transcription; Binds to transcription factors; Deacetylates FOXP3 (forkhead boxP3) that reduces Treg development and suppressive function
HDAC8 Nucleus Proliferation; Differentiation
IIA
HDAC4 Nucleus/Cytoplasm Differentiation, angiogenesis; Deacetylates BCL6 (B-cell lymphoma 6) which activates genes for lymphocyte activation
HDAC5 Nucleus/Cytoplasm Differentiation; Deacetylates BCL6 which activates genes for lymphocyte activation
HDAC7 Nucleus/Cytoplasm Angiogenesis; Suppresses Nur77 expression during TCR (T-cell receptor) negative selection; Regulates gene expressionduring TCR positive selection; Deacetylates BCL6 which activates genes for lymphocyte activation
HDAC9 Nucleus/Cytoplasm Deacetylates FOXP3, which reduces Treg development and immunosuppressive activity
IIB
HDAC6 Cytoplasm
Regulation of protein degradation both via aggresome and the regulation of Hsp90 chaperone activity; Migration;
Angiogenesis; Controls IgM and IgG levels upon antigen stimulation; T-cell migration; Immune synapse formation;
Deacetylates FOXP3 that decreases Treg development and immunosuppressive activity
HDAC10 Cytoplasm Angiogenesis
III
SIRT 1 Nucleus, Cytoplasm DNA repair/genome stability; Chromatin organization; Stress; Cancer
SIRT 2 Nucleus Mitosis; DNA repair; Chromatin condensation
SIRT 3 Mitochondria Cancer, chromatin silencing; DNA repair; Cellular stress
SIRT 4 Mitochondria have not yet been fully determined
SIRT 5 Mitochondria have not yet been fully determined
SIRT6 Nucleus DNA repair/genome stability; Telomeric chromatin/senescence
SIRT7 Nucleus Cellular transformation
IV HDAC11 Nucleus Regulates the protein stability of DNA replication factor CDT1 (chromatin licensing and DNA replication factor 1) andthe expression of IL-10; Suppresses IL10 expression in APCs (antigen presenting cells)
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In particular, HDAC1 and HDAC2 interact with each other to form the catalytic nucleus of
multiproteotic complexes including the Sin3A, NURD (nucleosome remodeling and deacetylation)
and Co-Rest complexes (co-repressor for element-1-silencing transcription factor). In the mammalian
cell nucleus the HDAC1 and HDAC2 are predominant, and the concomitant deletion of HDAC1 and
HDAC2 in T-cells [11] and ES (embryonic stem) cells induces a 50% decrease of total HDAC activity.
HDAC3 has generally been found associated with complexes with N-Cor and SMRT proteins [12].
HDAC6, on the other hand, has works in macro-complexes that are involved in the ubiquitin
pathway [13]. HDACs belonging to different classes can then coexist in the same complexes and
adjust their activity to each other (HDAC3 with either HDAC4 or HDAC7) [14,15]. Previous studies
demonstrated that individual HDAC members also manage the development and function of specific
T cell lineages. HDAC1 suppresses Th2 cytokine production in airway inflammation [16]. HDAC3 is
required for the development of both iNKT (invariant Natural Killer T cell) cells and CD8+ memory T
cells [17].
Although the role of HDAC4 in T cell lineages remained unclear, a series of studies has established
a potential link between HDAC4 and immune regulation. The expressions of multiple immune-related
transcription factors, including c-Jun [18], NF-κB, and Bcl-6 [19,20], are controlled by HDAC4.
One study conducted by Liu et al. reported that HDAC4 is differentially expressed in conventional T
cells and iNKT cells residing in various lymphoid organs. HDAC4 deletion in T cells did not affect T
cell development, maturation, or cytokine-secreting function [21].
The export of HDAC7 from the nucleus, which is necessary for the negative and positive selection
of the thymocytes, affects the expressions of adhesion molecules and cytokines together with their
receptors, that regulate the activity of cytotoxic T lymphocytes (CTL) [22,23]. Studies conducted
by Azagra et al. [24] explored the potential role of HDAC7 in B cell development by generating a
conditional knockout mouse model. The deletion of HDAC7 induces lymphopenia in peripheral organs
secondary to the arrest of early B cell development. HDAC7 suppress myeloid and T lymphocyte
genes in progenitors of the B lineage, interacting with myocyte enhancer factor 2C (MEFC2). In B cell
progenitors, HDAC7 is recruited to promoters and enhancers of target genes. When HDAC7 is absent
there is increased histone active marks [24]. HDAC6, HDAC9, and Sirt1 are able to mediate the histone
deacetylation of the Foxp3 gene, thus regulating Treg cell functions [25,26].
As previously reported, the activity of HDACs is regulated by different mechanisms such as
for example, post-translational modifications (acetylation and phosphorylation) and interactions
between proteins or the availability of cofactors essential for their enzymatic activity [27,28].
The cellular and physiological functions of acetylation are not limited to the regulation of gene
expression. The acetylation assumes a wider significance in many physiological processes, as it also
targets non-histone proteins as transcription factors, enzymes that repair DNA, chaperone proteins,
and structural proteins.
The activity of many intracellular proteins is regulated according to their acetylation [27]
and HDACs appear to be involved in a plethora of important cellular process comprising cell
proliferation, cell migration, angiogenesis, and protein–protein interaction [27]; as in the case of
the transcription factor STAT3. Through cytokine stimulation, STAT3 is activated and acetylated
before homodimerization and translocation into the nucleus. HDAC-mediated deacetylation prevents
dimerization and subsequent translocation into the nucleus [29,30].
The deacetylation of the HIF1 factor, expressed in the cell in response to available oxygen changes
and angiogenesis, instead, prevents the association with the VHL complex, its ubiquitination, and the
consequent degradation in the proteasome [31].
2.2. Biological Roles of Histone Deacetylase 6 (HDAC6)
HDAC6 has also been studied in cancers especially for its ability to coordinate a variety of
cellular processes that are important for cancer pathogenesis [32] (Figure 1). HDAC6 (class IIb)
is one isoform of a family of HDACs enzymes that catalyzes the removal of functional acetyl
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groups from proteins. It is mainly localized in the cytoplasm and has been described as a tubulin
deacetylase that has effects on microtubule-mediated processes through both deacetylase-dependent
and independent mechanisms [33,34]. HDAC6 itself exerts both enzymatic and non-enzymatic actions
on cell function. The growing interest for HDAC6-selective inhibitors is related to the modulation
of acetylation of non-histone regulatory proteins (α-tubulin) implicated in cancer initiation and
progression. Previous studies have focused on how the deacetylation of tubulin affects cell migration,
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Another possible role of HDACs in the development of hematological malignancies is related to
the functional network of HDAC6 and HSP90. Hsp90, chaperone heat shock protein, was the second
HDAC6 substrate identified in the cytoplasm after α-tubulin [37]. This protein is expressed in response
to cellular stress, acting on client proteins involved in proliferative and antiapoptotic signaling and
cell cycle control. HDAC6 modulates the chaperone activity of HSP90 through its deacetylation and,
indirectly can regulate the stability of the HSP90 which controls the stability of many oncoproteins [38].
Chaperone Hsp90 has been defined as components of the IKK complex which is the core element of
the NF-κB cascade and is involved in propagating the cellular response to inflammation.
IKK complex connected with its co-chaperone cdc37 works as a stabilizing factor of IKK through
interaction between cdc37 and the kinase domains of IKKα and IKKβ in NF-κβ signaling [39]. HDAC6
works as a regulator of the ubiquitin and proteasome system (UPS) and therefore of the cellular
response to protein misfolding [40–42]. HDAC6 is an element of the aggresome, a cellular structure
that constitutes the major site of degradation for misfolded protein aggregates, both non-ubiquitinated
and ubiquitinated misfolded proteins. The aggresome is an alternative pathway to the proteasome
for the elimination of misfolded protein accumulation [43]. Transformed cells accumulate more
misfolded proteins which are disposed by the proteasome and the aggresome [43,44]. Direction
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of misfolded proteins to the aggresome is essential for cell survival, since these proteins are form
cytotoxic aggregates that can interfere with normal cell function. HDAC6 binds both polyubiquitinated
misfolded proteins and dynein motors and act recruiting misfolded protein cargo to dynein motors for
transport to aggresomes. The polyubiquitinated misfolded proteins are transported by microtubules
to an autophagosome, where they are degraded via autophagy. This pathway is vital to multiple
myeloma (MM) cells that overproduce misfolded proteins and overburden the proteasome degradation
pathway [40,45]. Targeting both proteasomal and aggresomal protein degradation systems with
proteasome and HDAC6 inhibitors, respectively, induces accumulation of polyubiquitinated proteins,
activating the apoptotic cascades and synergistic cytotoxicity [42,46]. HDAC6 acts on GRP78
(78 kDa glucose-regulated protein), part of the unfolded protein response (UPR), inducing its
deacetylation. As consequence of the acetylation, GRP78 dissociates from PERK (protein kinase
RNA-like ER kinase) activating UPR and resulting in cell death [47]. HDAC6 is also involved in
autophagy through the deacetylation of autophagy linked proteins. HDAC6 acts deacetylating LC3B-II
(microtubule-associated protein 1 light chain 3), a central regulator of autophagy, involved in the
degradation of p62/SQSTM (sequestrome 1) [48].
HDAC6 is a critical regulator of the pro-apoptotic p53. Recent studies of the selective HDAC6
inhibitor A452 tested in colorectal cancer cell lines, demonstrated to affect p53 and HSP-90, increasing
the level of wild-type p53 as a result of the destabilization of MDM2, but decreasing mutant p53
and the consequent inhibition of Hsp90-mutant p53 complex formation. The treatment with A452
affected the HDAC6 expression, that was inversely associated with p53 acetylation at lysines 381/382,
related with p53 functional activation. A452 treatment blocked HDAC6 nuclear localization, resulting
in increased levels of acetylated p53 at Lys381/382. A452 interfered with the HDAC6-Hsp90 chaperone
machinery through acetylation and degradation of Hsp90 [49].
In addition, HDAC6 is also involved in the signaling pathway of PI3K (phosphoinositide
3-kinase)/AKT (protein kinase B) and mitogen activated protein kinase (MAPK)/ERK (extracellular
signal–regulated kinase) [50]. HDAC6 inhibition affects AKT and ERK dephosphorylation, responsible
for the inhibition of cell proliferation and the induction of cell death. Furthermore, HDAC6 inhibition
triggers the hyperacetylation of HSP90 leading to decreased levels of phosphorylated AKT and
ERK [51–53].
3. Abnormal Expression HDAC in Lymphoproliferative Disease
Many lymphoid malignancies show increased HDAC expression and activity. In lymphoma cells
gene deletions and mutations that inactivate or reduce HAT activity are often found. The reduction
of acetylation is associated with the proliferation and survival of lymphoma cells, while increased
acetylation is associated with cell tumor growth arrest and cell death. HDACs are considered promising
targets for cancer therapy because regulate a variety of cell functions that are involved in cell survival,
cell-cycle progression, angiogenesis, and immunity. Their activity is not only limited to histones but
also to non-histone proteins as signal transducers, transcription factors, and oncoproteins [54–57].
Class I HDAC (HDAC1–3 and 8) are predominantly upregulated in hematological malignancies
and their altered expression in some cancers has a significant prognostic implication. Different
studies have reported an overexpression of HDAC6 in primary and cultured myeloma and lymphoma
cells [42,58,59] (Table 2).
Mithraprabhu and colleagues characterized the expression pattern of HDACs in multiple
myeloma and correlated the expression with patient outcomes. In that study, the expression of
HDACs at a transcriptional level was evaluated utilizing both genetically heterogeneous HMCL
(human myeloma cell lines) and primary MM (multiple myeloma) cells compared to normal plasma
cells. They observed the overexpression of class I HDAC (HDAC1, HDAC2, HDAC3, and HDAC8) in
all HMCL tested, while only 2 of the class II (HDAC5 and HDAC10) were overexpressed. Furthermore,
the patients with higher levels of HDAC1–3, HDAC4, HDAC6, and HDAC11 transcripts demonstrated
a significantly shorter progression-free survival (PFS) [60]. Overexpression of HDAC1, HDAC2,
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and HDAC6 and of higher acetylation levels of histone H4, with respect to the normal lymphoid
tissue, have been reported by immunohistochemical studies conducted in patients with peripheral
T-cell lymphoma (PTCL), and diffuse B large cell lymphoma (DLBCL) [61]. The study conducted by
Marquard and collaborators in cutaneous T-cell lymphoma (CTCL) patients reported a high expression
level of HDAC1, HDAC2, and HDAC6, and an association between the levels of HDAC2 and histone
H4 acetylation and tumor aggressiveness. [59]. The high expression of HDAC has been confirmed in
the study conducted by Wang et al. in chronic lymphocytic leukemia (CLL) patients with a significant
increase in HDAC of class I including HDAC1 and HDAC3, class II including HADC6, HDAC7,
HDAC9, and HDAC10, and class III including SIRT1 and SIRT6 [62]. Additionally, the expression
of class I and class II HDACs has been studied in a panel of cell lines and tissue sections from
primary lymphoid tumors by Gloghini and colleagues. This study revealed that class I enzymes were
highly expressed in all non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) cell lines and
primary tumors studied, including the non-malignant reactive cells in the HL microenvironment.
Instead the class II enzyme HDAC6 was variably expressed in different types of lymphoid cell lines
compared with HDACs 5, 8, and 10. This variable expression of HDAC6 was not evident in the
primary lymphoma sections. Only 4% of primary diffuse large B cell lymphomas (DLBCL) and 18%
of HL cases demonstrated detectable levels of HDAC6 [63]. Since HDAC6 is rarely expressed in
primary lymphoma cases, Gloghini et al. asserted that it may not be an important therapeutic target
in selected lymphoid malignancies. It is important to know that in this study are included only few
cases of follicular lymphoma, mantle cell lymphoma, T-cell lymphoma, and plasmacytomas and the
expression pattern of HDAC6 in these histological subgroup remains undetermined. The expression of
HDAC1, 2, and 3 were studied also in 283 HL and Reed–Sternberg cells (HRSC) on tissue microarray
by Adams H. et al. All the HL that was possible to analyze expressed the HDAC2 (n = 194) and
HDAC3 (n = 207) isoforms in mostly 100% of HRSC and tumor-infiltrating lymphocytes. HDAC1 was
expressed in 169 of 179 analyzable HL in a mean 82% of HRSC and 172 out of 179 analyzable cases in a
mean of 83% of tumor-infiltrating lymphocytes [64].
Table 2. Expression of Histone Deacetylases (HDACs) in lymphoproliferative disease.
Class Members Expression of HDACs Increased in LymphoproliferativeDisease (Cell Lines and Primary Cell) Reference
I
HDAC1 MM, HL, MCL, DLBCL, ALCL, CLL PTCL, [59–64]
HDAC2 MM, HL, MCL, DLBCL, ALCL, PTCL [59–61,63,64]
HDAC3 MCL, CLL, DLBCL, HL; MM [59–65]
HDAC8 MM [60]
IIA
HDAC4 DLBCL, PTCL [61,63]
HDAC5 MM [60]
HDAC7 CLL, MCL [59,61–63]
HDAC9 CLL, MCL [59,62,63]
IIB
HDAC6 MM, MCL, DLBCL, PTCL, CTCL, CLL, [59–64]
HDAC10 CLL, MCL, HL [59,61–63]
III







IV HDAC11 MCL, HL [63]
MM = Multiple Myeloma; HL = Hodgkin’s lymphoma; MCL = Mantle Cell Lymphoma; DLCL = Diffuse Large B
Cell Lymphoma; ALCL = Anaplastic Cell Lymphoma; CLL = Chronic Lymphocytic Leukemia; PTCL = Peripheral T
cell Lymphoma; CTCL = Cutaneous T Cell Lymphoma.
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In the DLBCL and the follicular lymphomas the molecular mechanism leading to lymphoid
oncogenic transformation is mediated by overexpression of the transcriptional repressor B-cell
lymphoma 6 (BCL6) [66] that is associated with aberrant transcriptional repression through recruitment
of HDACs both of class I and class II [67].
Yang et al. conducted a study in leukemia patients observing a significant overexpression of
HDACs in CLL patients, with heterogeneous expression of HDACs in myeloid malignancies, such as
acute myeloid leukemia and myelodysplastic syndromes, without a leukemia-specific HDAC gene
expression profiles [68].
4. Anticancer Effects of HDAC Inhibitors and Their Roles in Lymphoproliferative Disease
4.1. Classification of HDAC Inhibitors: Specific and Non-Specific HDACis
Since HDACs modulate a variety of cellular functions involved in cell survival and in cancer
pathological conditions where the HDACs are overexpressed, the discovery of the association between
histone acetylation and malignant pathologies has sparked an interest for HDACs and several
new drugs have been developed in last years. All the HDACs require a Zn molecule in their
active site and are inhibited by the so called pan HDACis [69], except for the class III HDACs [70].
Based on their chemical structure HDACis can be classified in distinct groups: hydroxamates (TSA,
vorinostat/SAHA, ricolinostat/Acy-1215, citarinostat/Acy-241, tubacin, tubastatin) aliphatic acid
(phenylbutyrate, valporoic acid), benzamides (entinostat); and cyclic tetrapeptides (romidepsin) [71]
(Table 3).
Table 3. Histone deacetylase inhibitors (pan and selective) in clinical trials of
lymphoproliferative disease.
Class HDACis Target HDAC Clinical Trial Active in LymphoproliferativeDisease (clinicaltrials.gov)
Hidroxamic acids
Trichostatin A Pan Preclinical
Vorinostat/SAHA Pan * Phase I/II/III MM and lymphoma
Belinostat Pan ** Phase I/II Lymphoma
Panobinostat Pan *** Phase I/II MM and lymphoma
Givinostat Pan Phase I/II completed for MM and lymphoma
Resminostat Pan Phase II CTCL
Abexinostat Pan Phase I/II completed for MM and lymphoma
Quisinostat Pan Phase I/II completed for MM and lymphoma
Ricolinostat/Acy-1215 II selective Phase I/II clinical trials for MM and lymphoma
Citarinostat/Acy-241 II selective Phase I MM
Practilinostat I, II, IV /
CHR-3996 I /
Aliphatic acid
Valproic acid I, IIa Phase I/II completed for lymphoma
Butyric acid I, IIa Phase I/II completed for lymphoma
Phenylbutyric acid I, IIa Phase I/II completed for MM and lymphoma
Benzamides
Entinostat I Phase I/II completed—MM. Phase I/II—lymphoma
Tacedinaline I Phase II completed—MM.
4SC202 I Phase I completed—Advanced Hematologic
Malignancies
Mocetinostat I, IV Phase I/II clinical trials—lymphoma
Cyclic tetrapepides Romidepsin I
Approved for * CTCL and ** PTCL
Several studies of phase I/II lymphoma
Phase I/II clinical trials—MM.
Sirtuins inhibitors
Nicotinamide Class III Phase I/II MM. Phase I lymphoma
Sirtinol SIRT 1 and 2 Preclinical
Cambinol SIRT 1 and 2 Preclinical
Ex-527 SIRT 1 and 2 Preclinical
CTCL = Cutaneous T-cell lymphoma; PTCL = peripheral T-cell lymphoma; MM = Myeloma Multiple * approved by
FDA for CTCL; ** approved for PTCL; *** approved for MM.
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HDACis can have a specific inhibitory effect against some subtypes of HDACs (HDAC
isoform-selective inhibitors) or non-specific effects, against all types of HDACs (pan-inhibitors).
An important query is if pan-HDAC inhibitors are potentially more effective therapeutic agents
than HDAC-selective inhibitors. The non-specificity of currently available HDACis inhibitors results
in modulating the acetylation status of a wide range of protein targets, which may cause undesired
toxic effects. Selective inhibition may improve the efficacy and decrease the toxicity of pan-HDAC
inhibitors observed in the clinic.
Previous studies have demonstrated the ability of HDACis to enhance drug-induced cytotoxicity,
that has been related to activation of proapoptotic pathways. To enhance tumor cell chemosensitivity,
the HDACis have been used either individually or mostly in combination with other anti-cancer
drugs [72–74]. HDACis as single agents are effective in hematological disease given their pleiotropic
anticancer activities, however a growing number of studies have demonstrated more efficient and
tumor specific anticancer activities of HDAC inhibitors in combination with other drugs. Indeed,
several preclinical and clinical studies have indicated that HDAC inhibitors potentiate the efficacy
of a variety of drugs such as proteasome inhibitors, lenalidomide, pomalidomide, dexamethasone,
and venetoclax [75–80]. The synergistic effect between pan HDACis and proteasome inhibitors was
attributed to the ability of pan HDACis to repress HDAC6-dependent aggresome function [81,82].
The combination of new agents and HDAC inhibitors will help to develop non-chemotherapy-based
regimens that will maintain a high cure rate but will also reduce treatment-related toxicity.
4.2. Mechanisms of Actions of HDAC Inhibitors
HDAC inhibitors (HDACis) represent a class of targeted anticancer drugs that inhibit histone
deacetylases causing an increase of the acetylated level of histone, which in turn upgrade the expression
of the silenced regulatory genes in malignant cells [55,83,84]. HDACis treatment demonstrated
favorable results in B-cell lymphomas where the pathogenesis is secondary to the deregulation of the
BCL6 proto-oncogene. BCL6 is negatively regulated by p300 acetylation, which interferes with its
capacity to recruit HDACs. The pharmacological inhibition of HDAC activity in B-cell lymphoma
cells induces the accumulation of the inactive acetylated form of BCL6 causing cell cycle arrest and
apoptosis [85]. It is therefore possible to hypothesize the use of HDAC inhibitors to control the
activity of BCL-6 on gene expression through the modulation of its acetylation or by influencing the
accessibility of the transcription factor on specific DNA regions. Similarly, in aggressive B-NHLs,
the aberrant expression of c-Myc protein cooperates with HDAC to promote its transcriptional program
and neoplastic transformation [86]. c-Myc represents a valid therapy target to block the proliferation of
neoplastic cells as its inhibition has been shown to block the proliferation of the neoplastic clone [87].
Then abrogating the transcriptional activity of c-Myc by blocking the HDAC enzymes could represent
an alternative strategy to stop the guided lymphomagenesis from c-Myc [87].
Mechanisms of anticancer effects of HDACis are not uniform, depending on the type of cancer, on
the individual HDAC inhibitor, and its dose, as well as other factor [88]. In cancer cell lines HDACis
demonstrated several downstream effects, inducing cell cycle arrest in G1-S phase, activating apoptosis
via pro- and antiapoptotic mechanisms of cell death and inhibition of angiogenesis. They also affect the
endoplasmic stress response, and are involved in activation or inactivation of tumor suppressor genes
or oncogenes controlling cell growth and cell death [89]. Furthemore, HDACis have a pleiotropic effects
on signaling pathways that affect proliferation, differentiation, angiogenesis, and cell survival [55,84,90]
(Figure 2).
4.2.1. Cell Cycle Arrest
It has been shown that HDACis block cell proliferation and induce apoptosis in hematologic
and solid tumor malignancies cell lines causing cell cycle arrest in G1 or G2/M phase, principally
by altering the expression of proteins (cyclins, cyclin dependent kinase inhibitors) involved in cell
growth [91]. HDACis inhibit the expression of cyclin D [92,93] and cyclin A which reduces the activity
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of CDK4 and CDK2 leading to cell cycle arrest in G1. HDACis induce upregulation of p21, p27, and p16
leading to inhibition of cell cycle progression after binding to and inactivating CDK4 and CDK2 [94].
The increase of p21 expression is considered to be one of the most important mechanisms leading to
HDAC inhibitor mediated G1/S arrest [95–98].Int. J. Mol. Sci. 2018, 19, x  10 of 27 
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conversion of unconjugated microtubule linked protein light chain 3 (LC3-I) to conjugated light chain 3
(LC3-II), the transfer of LC3 to autophagosomes, the increase of acidic vesicular organelles and protein
expression associated with autophagy as well as the Atg5 gene related to autophagy [107–109].
4.2.4. Angiogenesis
The inhibition of HDAC can also block cell growth through the inhibition of angiogenesis.
Indeed, the HDACs inhibitors are able to increase the acetylation of the pro-angiogenic factor HIF-1α
determining its degradation and reducing the expression of the factor VEGF and angiopoietin [110].
4.2.5. Migration
The inhibitors of the HDACs are able to interfere with the downregulating process of metastasis
the CXCR4 chemokine receptor, important for homing medullary progenitors and circulating
endothelial cells, and prometastatic factors as the metal proteinase MMP2. In particular, through
inhibition of HDAC6, HDAC inhibitors reduce microtubule acetylation preventing the migration of
cancer cells [111].
4.2.6. Protein–Protein Interactions
HDACs are involved in multiple cellular processes that include protein stability, protein–protein
interactions. An important mechanism of the anticancer effect of HDACis is the regulation of cell
differentiation by activation of the mitogen-activated protein kinase (MAPK) pathway [112,113].
HDACis also promote acetylation of cytoplasmic proteins, altering function of several oncogenic
proteins [55,65,114–116].
In addition to the transcriptional effects, HDACis are also involved in acetylation status of
non-histone proteins implicated in critical regulatory processes as transcription factors (p53, c-Myc),
α-tubulin, hypoxia-inducible factor 1 alpha (HIF-1α), chaperons (HSP90), signaling mediators (STAT3),
β-catenin, and many others [54,117]. Finally, It has been reported that HDACis disturb proteasome
function and post-transcriptional protein modifications via mechanism that are undefined but may
include interference with the aggresome function that is responsible for the deposition of excess protein
destined for proteasomal degradation [42]. The expression of HDAC6, a microtubule-associated
deacetylase that interacts with polyubiquitinated proteins, is sufficient to rescue degeneration
associated with ubiquitin-proteasome system (UPS) dysfunction in vivo in an autophagy-dependent
manner [118–120]. HDAC6 provides an essential mechanistic link in the compensatory interaction of
induced autophagy when the UPS is impaired (Figures 1 and 2).
4.3. Pan-HDAC Inhibitors in Lymphoproliferative Disorders: Preclinical and Clinical Data
Pan-HDAC inhibitors can activate several antitumor pathways with potential therapeutic
advantages compared to HDAC isotype-specific inhibitors. HDACis are known for their cytotoxicity
that discriminate between normal and tumor cells [121] although it remains unclear why tumor cells
are more sensitive to HDACi-induced cell death than normal cells. Emerging data suggest that the
effects of HDACis in tumor cells may not be only depend on the specificity and selectivity of the
HDACis but also on the expression patterns of HDAC enzymes in tumor tissue. The antitumor activity
of HDACis has been confirmed in several preclinical and clinical trials for different type of tumors
including lymphoid malignancies [122].
Several pan-HDACis have been tested in clinical trials for the treatment of myeloma multiple
(MM), follicular lymphoma (FL), Hodgkin’s lymphoma (HL), cutaneous T-cell lymphoma (CTCL),
and Diffuse large B cell Lymphoma (DLBCL), and ongoing clinical trials are testing HDACis alone or
in combination with other cancer therapeutics for the treatment of B- and T-cell malignancies (Table 3).
So far four HDACis have been approved by the US Food and Drug Administration (FDA) for
clinical use. The first two FDA-approved inhibitors are the pan-HDACi, vorinostat (SAHA) [123],
which has been approved for the treatments of CTCL and is available as an oral medication, and the
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class I HDACi romidepsin (istodax, a bacterial cyclic peptide), which is administered intravenously
and has been granted FDA approval for CTCL treatment and for peripheral T cell lymphoma (PTCL)
(Table 3). HDACis treatment is especially effective in the treatment of CTCL, with favorable response
rates of 45% with romidepsin [124]. Romidepsin also induced complete and durable responses in
patients with relapsed or refractory peripheral T cell lymphoma across all major PTCL subtypes with
objective response rate of 25%, which led to the approval of single agent romidepsin for the treatment
of relapsed or refractory PTCL in the US [125]. According to clinicaltrials.gov, romidepsin is currently
evaluated in several studies, either as a single agent or in combination with other drugs mainly for
treatment of T-cell lymphoma. Belinostat (hydroxamate) was also approved in 2014 for relapsed and
refractory PTCL [126]. Finally, panobinostat, another hydroxamate, has been approved by the FDA for
refractory multiple myeloma [127]. However, like any anticancer agents, HDACis are also associated
with toxicities. The most common grade 3 and 4 adverse events observed with the use of HDAC
inhibitors were thrombocytopenia, neutropenia, anemia, fatigue, and diarrhea [125,128–130]. In two
independent phase 2 trials romidepsin showed an overall response rate of 34% with a durable response
of 13–15 months in patients with refractory CTCL and the most frequent toxicities of romidepsin
included nausea, vomiting, fatigue, and myelosuppression [131]. In some cases, the HDAC-induced
thrombocytopenia can be rapidly reversible upon withdrawal of the drug [71,132].
4.4. Selective HDAC6 Inhibitors in Lymphoproliferative Diseases: Pre-Clinical and Clinical Data
The pan-HDAC inhibitors toxicity might be due to their lack of specificity, reducing their
tolerability profile. In order to preserve the anticancer effect of HDACis while reducing the toxicity,
more selective compounds have been developed. The class IIb, HDAC6, has emerged as one potential
selective HDACi. Considering the implication of HDAC6 in cancer progression, this isoenzyme
represents a good pharmacological target for selective inhibition potentially reducing the toxicity
related to the off-target effects of pan-HDAC inhibitors. It is known that HDAC6 serve as a molecular
chaperone, it plays a role in regulating the aggresome function [133,134], and affects the acetylation
status of several proteins, including alpha-tubulin, that is important for the regulation of microtubule
stability and function. In hematological malignancies, HDAC6 has been reported to be overexpressed
in both B- and T-cell lymphomas [61] and its inhibition has demonstrated activity in preclinical
models of lymphomas and MM [135,136]. Different HDAC6 selective inhibitors have been synthesized,
and most of them belong to the class of hydroxamic acids [137,138] (Table 4). Small molecules such as
tubacin and tubastatin have been developed to target HDAC6 [42,139].
4.4.1. Tubacin
This molecule induces microtubule stabilization affecting cell mobility through α-tubulin
acetylation [140]. The inhibition of HDAC6 by tubacin results in the increase of Ku70 acetylation,
and the secondary release and activation of the proapoptotic protein BAX. The proteasomal degradation
of the antiapoptotic protein FLIP promotes the apoptosis [141,142]. The effects of tubacin has been
studied in MM and lymphoma. In MM cells, the result of HDAC6 inhibition by tubacin caused
acetylation of α-tubulin, induced apoptosis, decreased cell mobility, and inhibited the interaction of
HDAC6 with dynein, with a marked accumulation of ubiquitinated proteins [42]. Tubacin was also
combined with the proteasome inhibitor bortezomib. The combination of tubacin with bortezomib
induced synergistic antitumor activity in MM cells and primary bone marrow plasma cells, and with
a cytotoxicity mediated by c-Jun NH2-terminal kinase/caspase activation [42]. In lymphoma cells,
the overexpression of HDAC6 in primary lymphocytes and T cell lines increase cell migration in
response to cytokines. Knockdown of HDAC6 in T cells decreased chemotactic mobility independently
by its enzymatic activity [143]. In Burkitt’s lymphoma cell lines the inhibition of HDAC6 activity by
tubacin compromised the migration and invasion of the cells suppressing SDF-1α (stromal cell-derived
factor 1) [144]. Although the preclinical data obtained with tubacin were promising, unfortunately
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the high lipophilicity of this compound did not allow clinical investigations. Therefore, tubastatin A,
a tubacin derivative, was synthetized.
Table 4. HDAC6 inhibitors in lymphoproliferative disease.
HDAC6 Inhibitors LymphoproliferativeDisease
Preclinical and Clinical










Non-NHL + Carfilzomib [148] Phase 1/2 combo lena e dex in MM(NCT01583283) (active)
DLBCL, MCL, TCL + Bortezomib [136] Phase 1 combo poma and low-dose dex inrelapsed-and-refractory MM (NCT02189343) (active)
DLBCL
+ Ibrutinib [149] Phase 1/2 combo bort and dex in relapsed and
refractory MM (NCT01323751) (termined)+ Crizotinib [150]
FL, MCL, TCL + Bendamustine [151] Phase 1 /2 relapsed or refractory lymphoidmalignancies (NCT02091063) (recruiting)
Citarinostat (Acy-241) MM and MCL
+ Pomalidomide [80]
Phase 1 combo poma and dex in MM
(NCT02400242) (active)
+ Lenalidomide [80]
MM + anti-PD-L1 [152]
Tubacin
MM and lymphoma + Bortezomib [42,153] Preclinical studies. Compound not tested in clinical
trials: it is not optimized for oral deliveryBurkitt’s lymphoma [144,154]
Tubastatin A Lymphoma [155,156] Preclinical studies compound not tested in clinicaltrials: It is not optimized for oral delivery
4.4.2. Tubastatin
In preclinical studies in myeloma cell lines, tubastatin A synergistically enhanced both bortezomib
and carfilzomib-induced cytotoxicity [42,157]. Tubastatin A induced apoptosis and suppressed
lymphoma cell colony formation [157]. In preclinical studies in lymphoma cell, Lwin and colleagues,
revealed that tubastatin A induced apoptosis and inhibited clonogenic growth of lymphoma cells
both in the absence and presence of stroma adhesion, further supporting the role of HDAC6 in
cell adhesion-mediated clonogenicity [158]. Despite the positive results in the preclinical setting,
this compound demonstrated reduced bioavailability as well.
Both tubacin and tubastatin are not optimized for oral delivery and they have not been tested in
clinical trials.
Among HDAC6 inhibitors, only ricolinostat (ACY-1215, rocilinostat) is currently evaluated in
clinical trials [122].
4.4.3. Ricolinostat
This compound is a class IIb tubulin deacetylase inhibitor and is the first HDAC6 selective
inhibitor that showed promising results in pre-clinical testing and in clinical trials. Ricolinostat
is 10–15-fold selective for HDAC6, and 12-, 10-, and 11-fold less active against HDAC1, HDAC2,
and HDAC3 (class I HDACs). It has demonstrated in vitro and in vivo activity in MM and lymphoma
models, both as a single agent and in combination with other drugs [135,136].
While very well tolerated in the clinic, activity as a single agent however has been limited,
and combination strategies have proven more efficacious thus far. Combinations of ricolinostat with
lenalidomide, pomalidomide, and bortezomib are currently in clinical study for patients affected
by MM [159–162]. In myeloma cell lines, ricolinostat alone inhibited cell growth, induced α-tubulin
acetylation and cell death by apoptosis [135,145]. Synergistic activity has been observed in vitro study,
when ricolinostat was used in combination with the proteasome inhibitors bortezomib and carfilzomib.
The blockade of both the proteasome and aggresome pathways via combination therapy with the
proteasome inhibitors and ricolinostat has synergistic antitumor activity in MM [163]. In myeloma
cell lines, low doses of ricolinostat combined with bortezomib triggered synergistic effect resulting in
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prolonged endoplasmic reticulum stress and apoptosis via activation of caspases [146,148]. The efficacy
of the combination was also confirmed in vivo, in two different xenograft SCID mouse models [135].
Recently an in vitro study showed that ricolinostat induced upregulation of CD38 expression
on myeloma cells and had a synergistic effect in combination with daratumumab, an anti-CD38
antibody [164].
Experimental results also suggested that ricolinostat has potential efficacy in combination
with proven immunotherapeutic drugs such as immune checkpoint inhibitor and monoclonal
antibodies [75,162].
Results from clinical studies in myeloma, demonstrated that ricolinostat is quickly absorbed
with a half-life of ~3 h [165]. Concentration of ricolinostat increased in a dose dependent manner
from 40 to 160 mg, stabilizing at doses ≥160mg. Administration of ricolinostat (40–240 mg once
daily or 160 mg twice daily) with bortezomib (1.3 mg/m2) or lenalidomide (25 mg) did not affect
the pharmacokinetics of the single drugs. Vogl and colleagues conducted a study of ricolinostat in
combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple
myeloma [147]. Combination therapy with bortezomib and dexamethasone was well-tolerated during
dose escalation but led to dose-limiting diarrhea in an expansion cohort of ricolinostat at the dose
of 160 mg twice daily. Combination therapy of ricolinostat at the dose of 160 mg daily in a second
expansion cohort was well tolerated, with less severe hematologic, gastrointestinal, and constitutional
toxicities compared with published data on nonselective HDAC inhibitors. The overall response rate
of daily ricolinostat at ≥160 mg, in combination, was 37% and 14% among bortezomib-refractory
patients. Samples taken during therapy showed dose-dependent increases of acetylated tubulin in
peripheral blood lymphocytes. The combination of ricolinostat with bortezomib overcomes bortezomib
resistance in relapsed MM, with a favorable safety profile that offers potential advantages compared
with nonselective HDAC inhibition [147]. Ricolinostat has been also studied in combination with the
immunomodulator pomalidomide. When 4 mg of pomalidomide and 160 mg once daily or twice daily
of ricolinostat were administered, Cmax of ricolinostat was reached ≈1 h after the first daily dose and
then decreased to background levels within 6 h [165]. Pharmacodynamic analyses have demonstrated
that the mean fold increase in acetylated tubulin is greater than for acetylated histones, indicating
selective HDAC6 inhibition [78,160,166]. Ricolinostat has also been studied by Yee and colleagues in
combination with lenalidomide and dexamethasone in relapsed refractory myeloma patients [78].
In this study ricolinostat has been administered once daily at the dose of 60 mg on days
1–21 of a 28 day cycle, in combination with 25 mg of lenalidomide and 40 mg of dexamethasone.
The most common adverse events were fatigue and diarrhea. Pharmacodynamic studies indicated
that ricolinostat, at clinically relevant doses, inhibits HDAC6 while keeping a low and tolerable level
of class I HDAC inhibition [78].
Antitumor activity of ricolinostat alone and in combination has also been studied in lymphomas.
Amengual et al. demonstrated that targeting HDAC6 with ricolinostat in a panel of 16 lymphoma
cell lines (DLBCL, MCL, T-cell lymphoma) inhibited HDAC6 activity and sequestration of misfolded
proteins by disrupting transport to the aggresome through acetylation of α-tubulin. This effect
activated the UPR-apoptosis pathway shifting the cells towards death. These results were confirmed
in a xenograft mouse model of DLBCL [136]. Recently, a study conducted by the same authors
utilizing a panel of cell lines and primary patient samples of lymphoma, showed the synergistic effect
between ricolinostat and ibrutinib, confirmed in and in vivo xenograft mouse model of DLBCL [149].
Furthermore, the inhibition of HDAC6 leads to upregulation of the IRE1 pathway of the UPR. This in
turn was connected with upregulation of the B-cell receptor pathway. The confirmation of the
interaction between the UPR and the BCR pathway was further established by demonstrating synergy
between ricolinostat and ibrutinib across a panel of cell lines (ABC-DLBCL and MCL) known to be
sensitive to BTK inhibitors [149].
Interactions between ricolinostat and carfilzomib were examined in non-Hodgkin lymphoma
(NHL) models, including DLBCL and MCL [148]. In vitro, ricolinostat works synergistically with
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carfilzomib in multiple DLBCL and MCL systems, including bortezomib-resistant cells. The results
indicate that drugs combination induced cell death through multiple stress-related mechanisms
accompanied by increases in DNA damage (γH2A.X), G2–M arrest, and the marked induction of
mitochondrial injury. Combination treatment with carfilzomib and ricolinostat increased concentration
of reactive oxygen species (ROS). In an MCL xenograft model the treatment with carfilzomib and
ricolinostat was well tolerated, suppressing tumor growth and increased animals survival [148].
In a preclinical study conducted recently by our group [151] we tested the combination of
ricolinostat with bendamustine in lymphoma cell lines showing synergistic apoptosis-inducing effects
which is mediated by a corresponding effect on microtubule stabilization. The synergistic effect was
accompanied with the increased ROS, activation of caspase and modulated by Bcl-2 proteins family.
Exposure to ricolinostat induced the acetylation level of α-tubulin, the extend of which was not further
modified by bendamustine [151]. This demonstrates that HDAC6 plays an oncogenic role in DLBCL
via indirect activation of MET signaling.
A recent study in lymphoma, showed that HDAC6 plays an oncogenic role in DLBCL and the
combination of ricolinostat with crizotinib (ALK inhibitor) generated a strong synergistic effects.
In vivo efficacy of drug combination has been evaluated using a human DLBCL xenograft mouse
model. Ricolinostat (50 mg/kg) and crizotinib (50 mg/kg) in combination treatment significantly
inhibited tumor growth by ~87% [150].
A second HDAC6 inhibitor, derived from ricolinostat, is citarinostat (ACY-241), that is structurally
similar to ricolinostat but administered as a tablet rather than an oral solution.
4.4.4. Citarinostat
This agent is a second generation HDAC6 selective inhibitor with 13 to 18-fold selectivity towards
HDAC6 in comparison to HDAC1-3 [167]. Bae et al. demonstrated mechanisms whereby citarinostat in
a dose- and time-dependent fashion augments immune response and mediates anti-MM activity both
by decreasing CD138+ tumor cells and tumor-promoting immune cells and their expression of immune
checkpoints, as well as by promoting the activation of antigen specific CD8+ T cells [168]. Ray and
colleagues examined the combination of citarinostat with anti-PDL-1 antibody. For these studies
the authors used a co-culture model of immune effector cells (plasmacytoid dendritic cells, T cells,
and NK cell) and MM cells. Combination treatment triggered a more robust NK-cell mediated cytolytic
activity against MM cell than each agent alone [152]. Citarinostat showed efficacy in combination with
the immunomodulators lenalidomide and pomalidomide [80]. At the molecular level, combination
treatment resulted in increased apoptosis as well as cell cycle arrest, coupled with decreased expression
of pro-survival factors survivin, Myc, and IRF4. This combination effect in vitro translated to
significant efficacy at reducing tumor growth in an in vivo MM xenograft model [80]. These results
support the rationale of the Phase 1a/b clinical trial (NCT02400242) [122] exploring combination
treatment of citarinostat plus pomalidomide and dexamethasone in MM patients [80,122,169].
In addition, preliminary results of a preclinical study conducted recently by our group indicated
that citarinostat can be potentially combined with momelotinib, a JAK2/STAT3 inhibitor in lymphoid
malignancies [170]. In this study the antitumor activity of citarinostat/momelotinib combination
is mediated by the pro-apoptotic effect and by downregulation of JAK2/STAT3 pathways and its
downstream mediators [170]. Both, ricolinostat and citarinostat are evaluated as monotherapy and
in combination in phase 1 and 2 clinical trials in patients with multiple myeloma (NCT01997840,
NCT02400242) and lymphoid malignancies (NCT02091063) [122].
5. Future Developments of HDAC Inhibitors
Cancer drug research is a rapid expanding field, with new innovative products in active
development. Scientists are making a lot of progress in understanding how changes in DNA within
normal cells can cause them to turn into malignant cells. Advances in understanding DNA changes
in lymphoma cells have already led to improvements and highly effective drugs in these neoplasms.
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Ever since HDAC inhibitors were found active in various clinical trials, the efforts to discover more
efficient and selective HDAC inhibitors have been continually intensified.
Recently, the AK-DACi (a first-in-class alkylating deacetylase inhibiting molecule) tinostamustine
(EDO-S101) has been developed by Mundipharma EDO GmbH. It is a new drug that chemically
combines an alkylating agent with a pan-histone deacetylase inhibitor to simultaneously damage
DNA and block damage repairs [171]. The molecule was designed to maintain the fully functional
capacity of both compounds in order to increase the efficiency of both mechanisms decreasing toxicity
and providing more convenient administration. The rationale for using tinostamustine arises from
the hypothesis that histone acetylation induced by the novel radical would result in a more open
chromatin structure which would be particularly susceptible to the alkylating effect of bendamustine.
Compared to the single drugs, the combined function in one molecule showed superior activity.
Preclinical studies showed that the apoptosis induced by tinostamustine occurred at substantially
low concentrations following a very strong DNA damage response after exposure in vitro and in vivo.
Indeed, tinostamustine showed a strong preclinical activity in vivo against multiple myeloma (MM),
leukemia, and B-cell lymphomas with a toxicity profile similar to bendamustine [172]. López-Iglesias
and colleagues demonstrated that tinostamustine has a potent activity in MM cell lines and ex vivo
in cells isolated from MM patients, which was higher than that of bendamustine and this activity
was confirmed in vivo, in a CB17-SCID murine plasmacytoma model and in de novo Vk*MYC mice,
leading to a significant survival improvement in both models [173]. Furthermore, studies in vitro in
MM cell lines, conducted by Besses et al. revealed that tinostamustine, is a potent ER stress-inducing,
HDAC6-inhibiting, immunomodulatory, cell cycle inhibiting, pro-apoptotic, and c-MYC-antagonistic
activity, in contrast to vorinostat or bendamustine [174]. In addition, tinostamustine exhibits
strong synergy when given as part of combination therapy with agents such as bortezomib and
dexamethasone and may enhance the efficacy, offering the possibility of improved duration and
depth of response [174,175]. The first clinical study with tinostamustine is ongoing in patients with
haematological malignancies (clinicaltrials.gov identifier: NCT02576496) [122].
Recently, Karus Therapeutics Ltd. has designed and developed a novel class of highly-selective
inhibitors of HDAC6 with potential antineoplastic activity which combine the effectiveness of targeted
therapy and immunotherapy [176]. A HDAC6-specific inhibitor called KA2507, inhibits tumor growth
through regulation of aggresome formation, and inhibition of PD-L1 expression via decrease of
STAT3 phosphorylation [176]. Inhibition of HDAC6 confers a cancer immunotherapeutic response by
regulating immune checkpoint markers within the tumor microenvironment. Clinical trial is conducted
by Karus Therapeutics in patients with PD-L1 expressing solid tumors. (clinicaltrials.gov identifier:
NCT03008018) [122].
6. Conclusions
Over the past few decades, the growing understanding of epigenetics has led to a rapid expansion
of knowledge by researches on its role in cancer development. HDAC inhibitors represent an
encouraging class of antitumor drugs given the series of molecular and biological responses that
these agents can produce and minimal toxicity to normal cell. The therapeutic efficacy of the HDAC
inhibitors has been seen primarily in hematological malignancies with four of them approved for
cutaneous and peripheral T-cell lymphoma. Their use in combination with other agents reveal a more
useful application. Pan-HDAC can activate more antitumor pathways and this may lead toxicities due
to their lack of specificity. Furthermore, this limits duration of treatment especially when they are used
in combination with other agents with overlapping toxicities.
Recently, the attention has concentrated on development of more selective HDACis based on the
premise that such agents may be more tolerable than pan-HDACis. HDAC6 has become a promising
target molecule, due to its structure and functions, and for its non-histone substrates which play
a central role in malignancies development. The inhibition of HDAC6 is not expected to produce
severe toxicity, as documented by the good tolerability of compounds with preferential ability to
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inhibit this isoform [32,36,135,177,178]. HDAC6 stands out from the other HDACs in deacetylating
cytoplasmic proteins, in employing deacetylation-independent effects and in the success that has
been obtained in the development of isoform-specific inhibitors of its enzymatic action which have
reached clinical trial. Different HDAC6 selective inhibitors have been studied so far. Among the
several molecules with HDAC6 selective inhibition properties, ricolinostat and citarinostat emerge
as the most promising drugs, and are now under investigation in combination with dexamethasone
and bortezomib or an immunomodulatory agents for the treatment of relapsed and refractory MM.
Ricolinostat, the first-in-class HDAC6 selective inhibitor, has demonstrated good toxicity profile in
patients and preliminary evidence of anti-myeloma efficacy in combination with lenalidomide and
dexamethasone [78]. The antitumor activity of ricolinostat alone and in combination has also been
confirmed in lymphomas [136]. Citarinostat was designed as a second generation orally available
and HDAC6 selective inhibitor with improved solubility properties over the structurally related
inhibitor ricolinostat. Both ricolinostat and citarinostat have synergistic anticancer effects with
many other antitumor reagents suggesting that combination of this HDAC6 inhibitor and other
anticancer drugs can be very attractive therapeutic strategy. Therefore, it would be of interest for
future studies to assess the ability of selective HDAC inhibitors, to increase the cure rate of patients
with lymphoproliferative disease.
Author Contributions: M.C and S.P. conceived of the presented idea. M.C. performed literature search and wrote
the manuscript. S.P. critically reviewed the manuscript for intellectual content. All the authors have read and
approved the final manuscript.
Acknowledgments: This work was supported by grants from the Associazione “Angela Serra” per la Ricerca sul
Cancro di Modena, Italy.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Glozak, M.A.; Seto, E. Histone deacetylases and cancer. Oncogene 2007, 26, 5420–5432. [CrossRef] [PubMed]
2. Perri, F.; Longo, F.; Giuliano, M.; Sabbatino, F.; Favia, G.; Ionna, F.; Addeo, R.; Della Vittoria Scarpati, G.;
Di Lorenzo, G.; Pisconti, S. Epigenetic control of gene expression: Potential implications for cancer treatment.
Crit. Rev. Oncol. Hematol. 2017, 111, 166–172. [CrossRef] [PubMed]
3. Sharma, S.; Kelly, T.K.; Jones, P.A. Epigenetics in cancer. Carcinogenesis 2010, 31, 27–36. [CrossRef] [PubMed]
4. West, A.C.; Johnstone, R.W. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Investig. 2014,
124, 30–39. [CrossRef] [PubMed]
5. Jazirehi, A.R. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: Implications in
cancer therapy. Anticancer Drugs 2010, 21, 805–813. [CrossRef] [PubMed]
6. Schrump, D.S. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: Mechanisms and
potential clinical implications. Clin. Cancer Res. 2009, 15, 3947–3957. [CrossRef] [PubMed]
7. Marks, P.A.; Richon, V.M.; Rifkind, R.A. Histone deacetylase inhibitors: Inducers of differentiation or
apoptosis of transformed cells. J. Natl. Cancer Inst. 2000, 92, 1210–1216. [CrossRef] [PubMed]
8. Haberland, M.; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and
physiology: Implications for disease and therapy. Nat. Rev. Genet. 2009, 10, 32–42. [CrossRef] [PubMed]
9. Bassett, S.A.; Barnett, M.P.G. The role of dietary histone deacetylases (HDACs) inhibitors in health and
disease. Nutrients 2014, 6, 4273–4301. [CrossRef] [PubMed]
10. Villagra, A.; Cheng, F.; Wang, H.-W.; Suarez, I.; Glozak, M.; Maurin, M.; Nguyen, D.; Wright, K.L.;
Atadja, P.W.; Bhalla, K.; et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10
and immune tolerance. Nat. Immunol. 2009, 10, 92–100. [CrossRef] [PubMed]
11. Dovey, O.M.; Foster, C.T.; Conte, N.; Edwards, S.A.; Edwards, J.M.; Singh, R.; Vassiliou, G.; Bradley, A.;
Cowley, S.M. Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability
in mice. Blood 2013, 121, 1335–1344. [CrossRef] [PubMed]
12. Kelly, R.D.W.; Cowley, S.M. The physiological roles of histone deacetylase (HDAC) 1 and 2: Complex co-stars
with multiple leading parts. Biochem. Soc. Trans. 2013, 41, 741–749. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 2337 18 of 26
13. Seigneurin-Berny, D.; Verdel, A.; Curtet, S.; Lemercier, C.; Garin, J.; Rousseaux, S.; Khochbin, S. Identification
of components of the murine histone deacetylase 6 complex: Link between acetylation and ubiquitination
signaling pathways. Mol. Cell. Biol. 2001, 21, 8035–8044. [CrossRef] [PubMed]
14. Fischle, W.; Kiermer, V.; Dequiedt, F.; Verdin, E. The emerging role of class II histone deacetylases.
Biochem. Cell Biol. 2001, 79, 337–348. [CrossRef] [PubMed]
15. Fischle, W.; Dequiedt, F.; Hendzel, M.J.; Guenther, M.G.; Lazar, M.A.; Voelter, W.; Verdin, E. Enzymatic
activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and
SMRT/N-CoR. Mol. Cell 2002, 9, 45–57. [CrossRef]
16. Grausenburger, R.; Bilic, I.; Boucheron, N.; Zupkovitz, G.; El-Housseiny, L.; Tschismarov, R.; Zhang, Y.;
Rembold, M.; Gaisberger, M.; Hartl, A.; et al. Conditional deletion of histone deacetylase 1 in T cells leads to
enhanced airway inflammation and increased Th2 cytokine production. J. Immunol. 2010, 185, 3489–3497.
[CrossRef] [PubMed]
17. Hsu, F.-C.; Belmonte, P.J.; Constans, M.M.; Chen, M.W.; McWilliams, D.C.; Hiebert, S.W.; Shapiro, V.S.
Histone Deacetylase 3 Is Required for T Cell Maturation. J. Immunol. 2015, 195, 1578–1590. [CrossRef]
[PubMed]
18. Gordon, J.W.; Pagiatakis, C.; Salma, J.; Du, M.; Andreucci, J.J.; Zhao, J.; Hou, G.; Perry, R.L.; Dan, Q.;
Courtman, D.; et al. Protein kinase A-regulated assembly of a MEF2{middle dot}HDAC4 repressor complex
controls c-Jun expression in vascular smooth muscle cells. J. Biol. Chem. 2009, 284, 19027–19042. [CrossRef]
[PubMed]
19. Sandhu, S.K.; Volinia, S.; Costinean, S.; Galasso, M.; Neinast, R.; Santhanam, R.; Parthun, M.R.; Perrotti, D.;
Marcucci, G.; Garzon, R.; et al. miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional
activity of B-cell lymphoma 6 (BCL6) in the Eµ-miR-155 transgenic mouse model. Proc. Natl. Acad. Sci. USA
2012, 109, 20047–20052. [CrossRef] [PubMed]
20. Wang, A.H.; Bertos, N.R.; Vezmar, M.; Pelletier, N.; Crosato, M.; Heng, H.H.; Th’ng, J.; Han, J.; Yang, X.J.
HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor. Mol. Cell. Biol.
1999, 19, 7816–7827. [CrossRef] [PubMed]
21. Liu, Q.; Zhang, X.; Yin, C.; Chen, X.; Zhang, Z.; Brown, S.; Xie, H.; Zhou, L.; Mi, Q.-S. HDAC4 is expressed on
multiple T cell lineages but dispensable for their development and function. Oncotarget 2017, 8, 17562–17572.
[CrossRef] [PubMed]
22. Kasler, H.G.; Verdin, E. Histone deacetylase 7 functions as a key regulator of genes involved in both positive
and negative selection of thymocytes. Mol. Cell. Biol. 2007, 27, 5184–5200. [CrossRef] [PubMed]
23. Navarro, M.N.; Goebel, J.; Feijoo-Carnero, C.; Morrice, N.; Cantrell, D.A. Phosphoproteomic analysis reveals
an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T
lymphocytes. Nat. Immunol. 2011, 12, 352–361. [CrossRef] [PubMed]
24. Azagra, A.; Román-González, L.; Collazo, O.; Rodríguez-Ubreva, J.; de Yébenes, V.G.; Barneda-Zahonero, B.;
Rodríguez, J.; Castro de Moura, M.; Grego-Bessa, J.; Fernández-Duran, I.; et al. In vivo conditional deletion
of HDAC7 reveals its requirement to establish proper B lymphocyte identity and development. J. Exp. Med.
2016, 213, 2591–2601. [CrossRef] [PubMed]
25. De Zoeten, E.F.; Wang, L.; Sai, H.; Dillmann, W.H.; Hancock, W.W. Inhibition of HDAC9 increases T regulatory
cell function and prevents colitis in mice. Gastroenterology 2010, 138, 583–594. [CrossRef] [PubMed]
26. Beier, U.H.; Wang, L.; Han, R.; Akimova, T.; Liu, Y.; Hancock, W.W. Histone deacetylases 6 and 9 and sirtuin-1
control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms. Sci. Signal. 2012,
5, ra45. [CrossRef] [PubMed]
27. Minucci, S.; Pelicci, P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments
for cancer. Nat. Rev. Cancer 2006, 6, 38–51. [CrossRef] [PubMed]
28. Mercurio, C.; Minucci, S.; Pelicci, P.G. Histone deacetylases and epigenetic therapies of hematological
malignancies. Pharmacol. Res. 2010, 62, 18–34. [CrossRef] [PubMed]
29. Yuan, Z.-L.; Guan, Y.-J.; Chatterjee, D.; Chin, Y.E. Stat3 dimerization regulated by reversible acetylation of a
single lysine residue. Science 2005, 307, 269–273. [CrossRef] [PubMed]
30. Wang, R.; Cherukuri, P.; Luo, J. Activation of Stat3 sequence-specific DNA binding and transcription
by p300/CREB-binding protein-mediated acetylation. J. Biol. Chem. 2005, 280, 11528–11534. [CrossRef]
[PubMed]
Int. J. Mol. Sci. 2018, 19, 2337 19 of 26
31. Jeong, J.W.; Bae, M.K.; Ahn, M.Y.; Kim, S.H.; Sohn, T.K.; Bae, M.H.; Yoo, M.A.; Song, E.J.; Lee, K.J.; Kim, K.W.
Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 2002, 111, 709–720.
[CrossRef]
32. Aldana-Masangkay, G.I.; Sakamoto, K.M. The role of HDAC6 in cancer. J. Biomed. Biotechnol. 2011, 2011,
875824. [CrossRef] [PubMed]
33. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X.-F.; Yao, T.-P.
HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417, 455–458. [CrossRef] [PubMed]
34. Zhang, Y.; Li, N.; Caron, C.; Matthias, G.; Hess, D.; Khochbin, S.; Matthias, P. HDAC-6 interacts with and
deacetylates tubulin and microtubules in vivo. EMBO J. 2003, 22, 1168–1179. [CrossRef] [PubMed]
35. Di Giorgio, E.; Gagliostro, E.; Brancolini, C. Selective class IIa HDAC inhibitors: Myth or reality. Cell. Mol.
Life Sci. 2015, 72, 73–86. [CrossRef] [PubMed]
36. Valenzuela-Fernández, A.; Cabrero, J.R.; Serrador, J.M.; Sánchez-Madrid, F. HDAC6: A key regulator of
cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 2008, 18, 291–297. [CrossRef] [PubMed]
37. Yao, Y.-L.; Yang, W.-M. Beyond histone and deacetylase: An overview of cytoplasmic histone deacetylases
and their nonhistone substrates. J. Biomed. Biotechnol. 2011, 2011, 146493. [CrossRef] [PubMed]
38. Kovacs, J.J.; Murphy, P.J.M.; Gaillard, S.; Zhao, X.; Wu, J.-T.; Nicchitta, C.V.; Yoshida, M.; Toft, D.O.; Pratt, W.B.;
Yao, T.-P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.
Mol. Cell 2005, 18, 601–607. [CrossRef] [PubMed]
39. Hinz, M.; Broemer, M.; Arslan, S.C.; Otto, A.; Mueller, E.-C.; Dettmer, R.; Scheidereit, C. Signal responsiveness
of IkappaB kinases is determined by Cdc37-assisted transient interaction with Hsp90. J. Biol. Chem. 2007,
282, 32311–32319. [CrossRef] [PubMed]
40. Kawaguchi, Y.; Kovacs, J.J.; McLaurin, A.; Vance, J.M.; Ito, A.; Yao, T.P. The deacetylase HDAC6 regulates
aggresome formation and cell viability in response to misfolded protein stress. Cell 2003, 115, 727–738.
[CrossRef]
41. Boyault, C.; Zhang, Y.; Fritah, S.; Caron, C.; Gilquin, B.; Kwon, S.H.; Garrido, C.; Yao, T.-P.; Vourc’h, C.;
Matthias, P.; Khochbin, S. HDAC6 controls major cell response pathways to cytotoxic accumulation of
protein aggregates. Genes Dev. 2007, 21, 2172–2181. [CrossRef] [PubMed]
42. Hideshima, T.; Bradner, J.E.; Wong, J.; Chauhan, D.; Richardson, P.; Schreiber, S.L.; Anderson, K.C.
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in
multiple myeloma. Proc. Natl. Acad. Sci. USA 2005, 102, 8567–8572. [CrossRef] [PubMed]
43. Rodriguez-Gonzalez, A.; Lin, T.; Ikeda, A.K.; Simms-Waldrip, T.; Fu, C.; Sakamoto, K.M. Role of the
aggresome pathway in cancer: Targeting histone deacetylase 6-dependent protein degradation. Cancer Res.
2008, 68, 2557–2560. [CrossRef] [PubMed]
44. Boyault, C.; Sadoul, K.; Pabion, M.; Khochbin, S. HDAC6, at the crossroads between cytoskeleton and cell
signaling by acetylation and ubiquitination. Oncogene 2007, 26, 5468–5476. [CrossRef] [PubMed]
45. Ouyang, H.; Ali, Y.O.; Ravichandran, M.; Dong, A.; Qiu, W.; MacKenzie, F.; Dhe-Paganon, S.;
Arrowsmith, C.H.; Zhai, R.G. Protein aggregates are recruited to aggresome by histone deacetylase 6
via unanchored ubiquitin C termini. J. Biol. Chem. 2012, 287, 2317–2327. [CrossRef] [PubMed]
46. McConkey, D. Proteasome and HDAC: Who’s zooming who? Blood 2010, 116, 308–309. [CrossRef] [PubMed]
47. Rao, R.; Fiskus, W.; Yang, Y.; Lee, P.; Joshi, R.; Fernandez, P.; Mandawat, A.; Atadja, P.; Bradner, J.E.; Bhalla, K.
HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia
cells. Blood 2008, 112, 1886–1893. [CrossRef] [PubMed]
48. Liu, K.-P.; Zhou, D.; Ouyang, D.-Y.; Xu, L.-H.; Wang, Y.; Wang, L.-X.; Pan, H.; He, X.-H. LC3B-II deacetylation
by histone deacetylase 6 is involved in serum-starvation-induced autophagic degradation. Biochem. Biophys.
Res. Commun. 2013, 441, 970–975. [CrossRef] [PubMed]
49. Ryu, H.-W.; Shin, D.-H.; Lee, D.H.; Choi, J.; Han, G.; Lee, K.Y.; Kwon, S.H. HDAC6 deacetylates p53 at lysines
381/382 and differentially coordinates p53-induced apoptosis. Cancer Lett. 2017, 391, 162–171. [CrossRef]
[PubMed]
50. Lee, Y.-S.; Lim, K.-H.; Guo, X.; Kawaguchi, Y.; Gao, Y.; Barrientos, T.; Ordentlich, P.; Wang, X.-F.; Counter, C.M.;
Yao, T.-P. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res.
2008, 68, 7561–7569. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 2337 20 of 26
51. Chen, C.-S.; Weng, S.-C.; Tseng, P.-H.; Lin, H.-P.; Chen, C.-S. Histone acetylation-independent effect of histone
deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem.
2005, 280, 38879–38887. [CrossRef] [PubMed]
52. Kim, I.A.; No, M.; Lee, J.M.; Shin, J.H.; Oh, J.S.; Choi, E.J.; Kim, I.H.; Atadja, P.; Bernhard, E.J. Epigenetic
modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: Potential
role of histone deacetylase 6. Radiother. Oncol. 2009, 92, 125–132. [CrossRef] [PubMed]
53. Tien, S.-C.; Chang, Z.-F. Oncogenic Shp2 disturbs microtubule regulation to cause HDAC6-dependent ERK
hyperactivation. Oncogene 2014, 33, 2938–2946. [CrossRef] [PubMed]
54. Singh, B.N.; Zhang, G.; Hwa, Y.L.; Li, J.; Dowdy, S.C.; Jiang, S.-W. Nonhistone protein acetylation as cancer
therapy targets. Expert Rev. Anticancer Ther. 2010, 10, 935–954. [CrossRef] [PubMed]
55. Lane, A.A.; Chabner, B.A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 2009, 27, 5459–5468.
[CrossRef] [PubMed]
56. Marks, P.A.; Xu, W.-S. Histone deacetylase inhibitors: Potential in cancer therapy. J. Cell. Biochem. 2009, 107,
600–608. [CrossRef] [PubMed]
57. Glozak, M.A.; Sengupta, N.; Zhang, X.; Seto, E. Acetylation and deacetylation of non-histone proteins. Gene
2005, 363, 15–23. [CrossRef] [PubMed]
58. Fiskus, W.; Rao, R.; Fernandez, P.; Herger, B.; Yang, Y.; Chen, J.; Kolhe, R.; Mandawat, A.; Wang, Y.;
Joshi, R.; et al. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase
inhibitor-resistant acute myeloid leukemia cells. Blood 2008, 112, 2896–2905. [CrossRef] [PubMed]
59. Marquard, L.; Gjerdrum, L.M.; Christensen, I.J.; Jensen, P.B.; Sehested, M.; Ralfkiaer, E. Prognostic significance
of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.
Histopathology 2008, 53, 267–277. [CrossRef] [PubMed]
60. Mithraprabhu, S.; Kalff, A.; Chow, A.; Khong, T.; Spencer, A. Dysregulated Class I histone deacetylases are
indicators of poor prognosis in multiple myeloma. Epigenetics 2014, 9, 1511–1520. [CrossRef] [PubMed]
61. Marquard, L.; Poulsen, C.B.; Gjerdrum, L.M.; de Nully Brown, P.; Christensen, I.J.; Jensen, P.B.; Sehested, M.;
Johansen, P.; Ralfkiaer, E. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Histopathology 2009, 54, 688–698. [CrossRef] [PubMed]
62. Wang, J.C.; Kafeel, M.I.; Avezbakiyev, B.; Chen, C.; Sun, Y.; Rathnasabapathy, C.; Kalavar, M.; He, Z.;
Burton, J.; Lichter, S. Histone deacetylase in chronic lymphocytic leukemia. Oncology 2011, 81, 325–329.
[CrossRef] [PubMed]
63. Gloghini, A.; Buglio, D.; Khaskhely, N.M.; Georgakis, G.; Orlowski, R.Z.; Neelapu, S.S.; Carbone, A.;
Younes, A. Expression of histone deacetylases in lymphoma: Implication for the development of selective
inhibitors. Br. J. Haematol. 2009, 147, 515–525. [CrossRef] [PubMed]
64. Adams, H.; Fritzsche, F.R.; Dirnhofer, S.; Kristiansen, G.; Tzankov, A. Class I histone deacetylases 1, 2 and
3 are highly expressed in classical Hodgkin’s lymphoma. Expert Opin. Ther. Targets 2010, 14, 577–584.
[CrossRef] [PubMed]
65. Gupta, P.; Reid, R.C.; Iyer, A.; Sweet, M.J.; Fairlie, D.P. Towards isozyme-selective HDAC inhibitors for
interrogating disease. Curr. Top. Med. Chem. 2012, 12, 1479–1499. [CrossRef] [PubMed]
66. Shaffer, A.L.; Rosenwald, A.; Staudt, L.M. Lymphoid malignancies: The dark side of B-cell differentiation.
Nat. Rev. Immunol. 2002, 2, 920–932. [CrossRef] [PubMed]
67. Lemercier, C.; Brocard, M.-P.; Puvion-Dutilleul, F.; Kao, H.-Y.; Albagli, O.; Khochbin, S. Class II histone
deacetylases are directly recruited by BCL6 transcriptional repressor. J. Biol. Chem. 2002, 277, 22045–22052.
[CrossRef] [PubMed]
68. Yang, H.; Maddipoti, S.; Quesada, A.; Bohannan, Z.; Cabrero Calvo, M.; Colla, S.; Wei, Y.; Estecio, M.;
Wierda, W.; Bueso-Ramos, C.; et al. Analysis of class I and II histone deacetylase gene expression in human
leukemia. Leuk. Lymphoma 2015, 56, 3426–3433. [CrossRef] [PubMed]
69. Prince, H.M.; Bishton, M.J.; Harrison, S.J. Clinical studies of histone deacetylase inhibitors. Clin. Cancer Res.
2009, 15, 3958–3969. [CrossRef] [PubMed]
70. Frye, R.A. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins
(sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem. Biophys.
Res. Commun. 1999, 260, 273–279. [CrossRef] [PubMed]
71. Mottamal, M.; Zheng, S.; Huang, T.L.; Wang, G. Histone deacetylase inhibitors in clinical studies as templates
for new anticancer agents. Molecules 2015, 20, 3898–3941. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 2337 21 of 26
72. Ai, T.; Cui, H.; Chen, L. Multi-targeted histone deacetylase inhibitors in cancer therapy. Curr. Med. Chem.
2012, 19, 475–487. [CrossRef] [PubMed]
73. Matthews, G.M.; Lefebure, M.; Doyle, M.A.; Shortt, J.; Ellul, J.; Chesi, M.; Banks, K.M.; Vidacs, E.;
Faulkner, D.; Atadja, P.; et al. Preclinical screening of histone deacetylase inhibitors combined with ABT-737,
rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. Cell Death Dis. 2013, 4, e798.
[CrossRef] [PubMed]
74. Wanczyk, M.; Roszczenko, K.; Marcinkiewicz, K.; Bojarczuk, K.; Kowara, M.; Winiarska, M. HDACi—Going
through the mechanisms. Front. Biosci. (Landmark Ed.) 2011, 16, 340–359. [CrossRef] [PubMed]
75. Hideshima, T.; Cottini, F.; Ohguchi, H.; Jakubikova, J.; Gorgun, G.; Mimura, N.; Tai, Y.-T.; Munshi, N.C.;
Richardson, P.G.; Anderson, K.C. Rational combination treatment with histone deacetylase inhibitors and
immunomodulatory drugs in multiple myeloma. Blood Cancer J. 2015, 5, e312. [CrossRef] [PubMed]
76. Heider, U.; von Metzler, I.; Kaiser, M.; Rosche, M.; Sterz, J.; Rötzer, S.; Rademacher, J.; Jakob, C.; Fleissner, C.;
Kuckelkorn, U.; et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome
inhibitor bortezomib in mantle cell lymphoma. Eur. J. Haematol. 2008, 80, 133–142. [CrossRef] [PubMed]
77. Gao, L.; Gao, M.; Yang, G.; Tao, Y.; Kong, Y.; Yang, R.; Meng, X.; Ai, G.; Wei, R.; Wu, H.; et al. Synergistic
Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and
ERK1/2. Biomed. Res. Int. 2015, 2015, 459052. [CrossRef] [PubMed]
78. Yee, A.J.; Bensinger, W.I.; Supko, J.G.; Voorhees, P.M.; Berdeja, J.G.; Richardson, P.G.; Libby, E.N.; Wallace, E.E.;
Birrer, N.E.; Burke, J.N.; et al. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory
multiple myeloma: A multicentre phase 1b trial. Lancet Oncol. 2016, 17, 1569–1578. [CrossRef]
79. Cyrenne, B.M.; Lewis, J.M.; Weed, J.G.; Carlson, K.R.; Mirza, F.N.; Foss, F.M.; Girardi, M. Synergy of BCL2
and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients. Blood
2017, 130, 2073–2083. [CrossRef] [PubMed]
80. North, B.J.; Almeciga-Pinto, I.; Tamang, D.; Yang, M.; Jones, S.S.; Quayle, S.N. Enhancement of pomalidomide
anti-tumor response with ACY-241, a selective HDAC6 inhibitor. PLoS ONE 2017, 12, e0173507. [CrossRef]
[PubMed]
81. Catley, L.; Weisberg, E.; Kiziltepe, T.; Tai, Y.-T.; Hideshima, T.; Neri, P.; Tassone, P.; Atadja, P.; Chauhan, D.;
Munshi, N.C.; et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin
hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood
2006, 108, 3441–3449. [CrossRef] [PubMed]
82. Dasmahapatra, G.; Lembersky, D.; Kramer, L.; Fisher, R.I.; Friedberg, J.; Dent, P.; Grant, S. The pan-HDAC
inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells
in vitro and in vivo. Blood 2010, 115, 4478–4487. [CrossRef] [PubMed]
83. Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev.
Drug Discov. 2006, 5, 769–784. [CrossRef] [PubMed]
84. Xu, W.S.; Parmigiani, R.B.; Marks, P.A. Histone deacetylase inhibitors: Molecular mechanisms of action.
Oncogene 2007, 26, 5541–5552. [CrossRef] [PubMed]
85. Bereshchenko, O.R.; Gu, W.; Dalla-Favera, R. Acetylation inactivates the transcriptional repressor BCL6.
Nat. Genet. 2002, 32, 606–613. [CrossRef] [PubMed]
86. Kurland, J.F.; Tansey, W.P. Myc-mediated transcriptional repression by recruitment of histone deacetylase.
Cancer Res. 2008, 68, 3624–3629. [CrossRef] [PubMed]
87. Gomez-Curet, I.; Perkins, R.S.; Bennett, R.; Feidler, K.L.; Dunn, S.P.; Krueger, L.J. c-Myc inhibition negatively
impacts lymphoma growth. J. Pediatr. Surg. 2006, 41, 207–211, discussion 207–211. [CrossRef] [PubMed]
88. Kretsovali, A.; Hadjimichael, C.; Charmpilas, N. Histone deacetylase inhibitors in cell pluripotency,
differentiation, and reprogramming. Stem Cells Int. 2012, 2012, 184154. [CrossRef] [PubMed]
89. Piekarz, R.L.; Bates, S.E. Epigenetic modifiers: Basic understanding and clinical development.
Clin. Cancer Res. 2009, 15, 3918–3926. [CrossRef] [PubMed]
90. Peart, M.J.; Smyth, G.K.; van Laar, R.K.; Bowtell, D.D.; Richon, V.M.; Marks, P.A.; Holloway, A.J.;
Johnstone, R.W. Identification and functional significance of genes regulated by structurally different histone
deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 2005, 102, 3697–3702. [CrossRef] [PubMed]
91. Peart, M.J.; Tainton, K.M.; Ruefli, A.A.; Dear, A.E.; Sedelies, K.A.; O’Reilly, L.A.; Waterhouse, N.J.;
Trapani, J.A.; Johnstone, R.W. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors.
Cancer Res. 2003, 63, 4460–4471. [PubMed]
Int. J. Mol. Sci. 2018, 19, 2337 22 of 26
92. Kawamata, N.; Chen, J.; Koeffler, H.P. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses
translation of cyclin D1 in mantle cell lymphoma cells. Blood 2007, 110, 2667–2673. [CrossRef] [PubMed]
93. Sandor, V.; Senderowicz, A.; Mertins, S.; Sackett, D.; Sausville, E.; Blagosklonny, M.V.; Bates, S.E.
P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone
deacetylase inhibitor FR901228. Br. J. Cancer 2000, 83, 817–825. [CrossRef] [PubMed]
94. Abukhdeir, A.M.; Park, B.H. P21 and p27: Roles in carcinogenesis and drug resistance. Expert Rev. Mol. Med.
2008, 10, e19. [CrossRef] [PubMed]
95. Sun, L.; He, Q.; Tsai, C.; Lei, J.; Chen, J.; Vienna Makcey, L.; Coy, D.H. HDAC inhibitors suppressed small
cell lung cancer cell growth and enhanced the suppressive effects of receptor-targeting cytotoxins via
upregulating somatostatin receptor II. Am. J. Transl. Res. 2018, 10, 545–553. [PubMed]
96. Zhou, H.; Cai, Y.; Liu, D.; Li, M.; Sha, Y.; Zhang, W.; Wang, K.; Gong, J.; Tang, N.; Huang, A.; et al.
Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis
via p21Waf1/Cip1 and p19INK4d upregulation in hepatocellular carcinoma. Cell Prolif. 2018, 51, e12447.
[CrossRef] [PubMed]
97. Dong, Z.; Yang, Y.; Liu, S.; Lu, J.; Huang, B.; Zhang, Y. HDAC inhibitor PAC-320 induces G2/M cell cycle
arrest and apoptosis in human prostate cancer. Oncotarget 2018, 9, 512–523. [CrossRef] [PubMed]
98. Mensah, A.A.; Kwee, I.; Gaudio, E.; Rinaldi, A.; Ponzoni, M.; Cascione, L.; Fossati, G.; Stathis, A.; Zucca, E.;
Caprini, G.; et al. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to
the importance of CDKN1A expression levels in mediating their anti-tumor response. Oncotarget 2015, 6,
5059–5071. [CrossRef] [PubMed]
99. Miller, C.P.; Singh, M.M.; Rivera-Del Valle, N.; Manton, C.A.; Chandra, J. Therapeutic strategies to enhance
the anticancer efficacy of histone deacetylase inhibitors. J. Biomed. Biotechnol. 2011, 2011, 514261. [CrossRef]
[PubMed]
100. Fulda, S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr. Cancer Drug Targets 2008, 8,
132–140. [CrossRef] [PubMed]
101. Matthews, G.M.; Newbold, A.; Johnstone, R.W. Intrinsic and extrinsic apoptotic pathway signaling as
determinants of histone deacetylase inhibitor antitumor activity. Adv. Cancer Res. 2012, 116, 165–197.
[CrossRef] [PubMed]
102. Ruefli, A.A.; Ausserlechner, M.J.; Bernhard, D.; Sutton, V.R.; Tainton, K.M.; Kofler, R.; Smyth, M.J.;
Johnstone, R.W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic
acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive
oxygen species. Proc. Natl. Acad. Sci. USA 2001, 98, 10833–10838. [CrossRef] [PubMed]
103. Powis, G.; Mustacich, D.; Coon, A. The role of the redox protein thioredoxin in cell growth and cancer.
Free Radic. Biol. Med. 2000, 29, 312–322. [CrossRef]
104. Hrebackova, J.; Hrabeta, J.; Eckschlager, T. Valproic acid in the complex therapy of malignant tumors.
Curr. Drug Targets 2010, 11, 361–379. [CrossRef] [PubMed]
105. Oh, M.; Choi, I.-K.; Kwon, H.J. Inhibition of histone deacetylase1 induces autophagy. Biochem. Biophys.
Res. Commun. 2008, 369, 1179–1183. [CrossRef] [PubMed]
106. Bánréti, A.; Sass, M.; Graba, Y. The emerging role of acetylation in the regulation of autophagy. Autophagy
2013, 9, 819–829. [CrossRef] [PubMed]
107. Kabeya, Y.; Mizushima, N.; Ueno, T.; Yamamoto, A.; Kirisako, T.; Noda, T.; Kominami, E.; Ohsumi, Y.;
Yoshimori, T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes
after processing. EMBO J. 2000, 19, 5720–5728. [CrossRef] [PubMed]
108. Ohsumi, Y. Molecular dissection of autophagy: Two ubiquitin-like systems. Nat. Rev. Mol. Cell Biol. 2001, 2,
211–216. [CrossRef] [PubMed]
109. Liang, X.H.; Jackson, S.; Seaman, M.; Brown, K.; Kempkes, B.; Hibshoosh, H.; Levine, B. Induction of
autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999, 402, 672–676. [CrossRef] [PubMed]
110. Deroanne, C.F.; Bonjean, K.; Servotte, S.; Devy, L.; Colige, A.; Clausse, N.; Blacher, S.; Verdin, E.; Foidart, J.-M.;
Nusgens, B.V.; et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial
growth factor signaling. Oncogene 2002, 21, 427–436. [CrossRef] [PubMed]
111. Liu, L.-T.; Chang, H.-C.; Chiang, L.-C.; Hung, W.-C. Histone deacetylase inhibitor up-regulates RECK to
inhibit MMP-2 activation and cancer cell invasion. Cancer Res. 2003, 63, 3069–3072. [PubMed]
Int. J. Mol. Sci. 2018, 19, 2337 23 of 26
112. Khan, O.; La Thangue, N.B. HDAC inhibitors in cancer biology: Emerging mechanisms and clinical
applications. Immunol. Cell Biol. 2012, 90, 85–94. [CrossRef] [PubMed]
113. Rosato, R.R.; Grant, S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol. Ther. 2003, 2, 30–37.
[CrossRef] [PubMed]
114. Gu, W.; Roeder, R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal
domain. Cell 1997, 90, 595–606. [CrossRef]
115. Zhang, X.D.; Gillespie, S.K.; Borrow, J.M.; Hersey, P. The histone deacetylase inhibitor suberic
bishydroxamate: A potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL)
induced apoptosis. Biochem. Pharmacol. 2003, 66, 1537–1545. [CrossRef]
116. Bali, P.; Pranpat, M.; Bradner, J.; Balasis, M.; Fiskus, W.; Guo, F.; Rocha, K.; Kumaraswamy, S.; Boyapalle, S.;
Atadja, P.; et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat
shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 2005,
280, 26729–26734. [CrossRef] [PubMed]
117. Kim, H.-J.; Bae, S.-C. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as
anti-cancer drugs. Am. J. Transl. Res. 2011, 3, 166–179. [PubMed]
118. Trüe, O.; Matthias, P. Interplay between histone deacetylases and autophagy–from cancer therapy to
neurodegeneration. Immunol. Cell Biol. 2012, 90, 78–84. [CrossRef] [PubMed]
119. Pandey, U.B.; Nie, Z.; Batlevi, Y.; McCray, B.A.; Ritson, G.P.; Nedelsky, N.B.; Schwartz, S.L.; DiProspero, N.A.;
Knight, M.A.; Schuldiner, O.; et al. HDAC6 rescues neurodegeneration and provides an essential link
between autophagy and the UPS. Nature 2007, 447, 859–863. [CrossRef] [PubMed]
120. Pandey, U.B.; Batlevi, Y.; Baehrecke, E.H.; Taylor, J.P. HDAC6 at the intersection of autophagy,
the ubiquitin-proteasome system and neurodegeneration. Autophagy 2007, 3, 643–645. [CrossRef] [PubMed]
121. Zain, J.; O’Connor, O.A. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
Investig. New Drugs 2010, 28 (Suppl. 1), S58–S78. [CrossRef]
122. Home—ClinicalTrials.gov. Available online: https://clinicaltrials.gov/ (accessed on 19 June 2018).
123. Duvic, M.; Vu, J. Vorinostat: A new oral histone deacetylase inhibitor approved for cutaneous T-cell
lymphoma. Expert Opin. Investig. Drugs 2007, 16, 1111–1120. [CrossRef] [PubMed]
124. Foss, F.; Duvic, M.; Lerner, A.; Waksman, J.; Whittaker, S. Clinical Efficacy of Romidepsin in Tumor Stage and
Folliculotropic Mycosis Fungoides. Clin. Lymphoma Myeloma Leuk. 2016, 16, 637–643. [CrossRef] [PubMed]
125. Coiffier, B.; Pro, B.; Prince, H.M.; Foss, F.; Sokol, L.; Greenwood, M.; Caballero, D.; Borchmann, P.;
Morschhauser, F.; Wilhelm, M.; et al. Results from a pivotal, open-label, phase II study of romidepsin
in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J. Clin. Oncol. 2012, 30,
631–636. [CrossRef] [PubMed]
126. Lee, H.-Z.; Kwitkowski, V.E.; Del Valle, P.L.; Ricci, M.S.; Saber, H.; Habtemariam, B.A.; Bullock, J.;
Bloomquist, E.; Li Shen, Y.; Chen, X.-H.; et al. FDA Approval: Belinostat for the Treatment of Patients
with Relapsed or Refractory Peripheral T-cell Lymphoma. Clin. Cancer Res. 2015, 21, 2666–2670. [CrossRef]
[PubMed]
127. San-Miguel, J.F.; Hungria, V.T.M.; Yoon, S.-S.; Beksac, M.; Dimopoulos, M.A.; Elghandour, A.;
Jedrzejczak, W.W.; Günther, A.; Nakorn, T.N.; Siritanaratkul, N.; et al. Panobinostat plus bortezomib and
dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed
and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014,
15, 1195–1206. [CrossRef]
128. Subramanian, S.; Bates, S.E.; Wright, J.J.; Espinoza-Delgado, I.; Piekarz, R.L. Clinical Toxicities of Histone
Deacetylase Inhibitors. Pharmaceuticals 2010, 3, 2751–2767. [CrossRef] [PubMed]
129. Mackay, H.J.; Hirte, H.; Colgan, T.; Covens, A.; MacAlpine, K.; Grenci, P.; Wang, L.; Mason, J.; Pham, P.-A.;
Tsao, M.-S.; et al. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum
resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. Eur. J. Cancer 2010, 46,
1573–1579. [CrossRef] [PubMed]
130. Pili, R.; Salumbides, B.; Zhao, M.; Altiok, S.; Qian, D.; Zwiebel, J.; Carducci, M.A.; Rudek, M.A. Phase I study
of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid
tumours. Br. J. Cancer 2012, 106, 77–84. [CrossRef] [PubMed]
131. Kim, M.; Thompson, L.A.; Wenger, S.D.; O’Bryant, C.L. Romidepsin: A histone deacetylase inhibitor for
refractory cutaneous T-cell lymphoma. Ann. Pharmacother. 2012, 46, 1340–1348. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 2337 24 of 26
132. Bishton, M.J.; Harrison, S.J.; Martin, B.P.; McLaughlin, N.; James, C.; Josefsson, E.C.; Henley, K.J.; Kile, B.T.;
Prince, H.M.; Johnstone, R.W. Deciphering the molecular and biologic processes that mediate histone
deacetylase inhibitor-induced thrombocytopenia. Blood 2011, 117, 3658–3668. [CrossRef] [PubMed]
133. Harada, T.; Hideshima, T.; Anderson, K.C. Histone deacetylase inhibitors in multiple myeloma: From bench
to bedside. Int. J. Hematol. 2016, 104, 300–309. [CrossRef] [PubMed]
134. Simms-Waldrip, T.; Rodriguez-Gonzalez, A.; Lin, T.; Ikeda, A.K.; Fu, C.; Sakamoto, K.M. The aggresome
pathway as a target for therapy in hematologic malignancies. Mol. Genet. Metab. 2008, 94, 283–286. [CrossRef]
[PubMed]
135. Santo, L.; Hideshima, T.; Kung, A.L.; Tseng, J.-C.; Tamang, D.; Yang, M.; Jarpe, M.; van Duzer, J.H.;
Mazitschek, R.; Ogier, W.C.; et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of
a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012,
119, 2579–2589. [CrossRef] [PubMed]
136. Amengual, J.E.; Johannet, P.; Lombardo, M.; Zullo, K.; Hoehn, D.; Bhagat, G.; Scotto, L.; Jirau-Serrano, X.;
Radeski, D.; Heinen, J.; et al. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6
Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. Clin. Cancer Res. 2015, 21, 4663–4675.
[CrossRef] [PubMed]
137. Wang, X.-X.; Wan, R.-Z.; Liu, Z.-P. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Eur. J. Med. Chem. 2018, 143, 1406–1418. [CrossRef] [PubMed]
138. Dallavalle, S.; Pisano, C.; Zunino, F. Development and therapeutic impact of HDAC6-selective inhibitors.
Biochem. Pharmacol. 2012, 84, 756–765. [CrossRef] [PubMed]
139. Namdar, M.; Perez, G.; Ngo, L.; Marks, P.A. Selective inhibition of histone deacetylase 6 (HDAC6) induces
DNA damage and sensitizes transformed cells to anticancer agents. Proc. Natl. Acad. Sci. USA 2010, 107,
20003–20008. [CrossRef] [PubMed]
140. Haggarty, S.J.; Koeller, K.M.; Wong, J.C.; Grozinger, C.M.; Schreiber, S.L. Domain-selective small-molecule
inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. USA 2003,
100, 4389–4394. [CrossRef] [PubMed]
141. Subramanian, C.; Jarzembowski, J.A.; Opipari, A.W.; Castle, V.P.; Kwok, R.P.S. HDAC6 deacetylates Ku70
and regulates Ku70-Bax binding in neuroblastoma. Neoplasia 2011, 13, 726–734. [CrossRef] [PubMed]
142. Kerr, E.; Holohan, C.; McLaughlin, K.M.; Majkut, J.; Dolan, S.; Redmond, K.; Riley, J.; McLaughlin, K.;
Stasik, I.; Crudden, M.; et al. Identification of an acetylation-dependant Ku70/FLIP complex that regulates
FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death Differ. 2012, 19, 1317–1327. [CrossRef]
[PubMed]
143. Cabrero, J.R.; Serrador, J.M.; Barreiro, O.; Mittelbrunn, M.; Naranjo-Suárez, S.; Martín-Cófreces, N.;
Vicente-Manzanares, M.; Mazitschek, R.; Bradner, J.E.; Avila, J.; et al. Lymphocyte chemotaxis is regulated by
histone deacetylase 6, independently of its deacetylase activity. Mol. Biol. Cell 2006, 17, 3435–3445. [CrossRef]
[PubMed]
144. Ding, N.; Ping, L.; Feng, L.; Zheng, X.; Song, Y.; Zhu, J. Histone deacetylase 6 activity is critical for the
metastasis of Burkitt’s lymphoma cells. Cancer Cell Int. 2014, 14, 139. [CrossRef] [PubMed]
145. Mithraprabhu, S.; Khong, T.; Jones, S.S.; Spencer, A. Histone deacetylase (HDAC) inhibitors as single agents
induce multiple myeloma cell death principally through the inhibition of class I HDAC. Br. J. Haematol. 2013,
162, 559–562. [CrossRef] [PubMed]
146. Mishima, Y.; Santo, L.; Eda, H.; Cirstea, D.; Nemani, N.; Yee, A.J.; O’Donnell, E.; Selig, M.K.; Quayle, S.N.;
Arastu-Kapur, S.; et al. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates
carfilzomib-induced multiple myeloma cell death. Br. J. Haematol. 2015, 169, 423–434. [CrossRef] [PubMed]
147. Vogl, D.T.; Raje, N.; Jagannath, S.; Richardson, P.; Hari, P.; Orlowski, R.; Supko, J.G.; Tamang, D.; Yang, M.;
Jones, S.S.; et al. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with
Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Clin. Cancer Res. 2017, 23,
3307–3315. [CrossRef] [PubMed]
148. Dasmahapatra, G.; Patel, H.; Friedberg, J.; Quayle, S.N.; Jones, S.S.; Grant, S. In vitro and in vivo interactions
between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib
in non-Hodgkin lymphoma cells. Mol. Cancer Ther. 2014, 13, 2886–2897. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 2337 25 of 26
149. Amengual, J.E.; Prabhu, S.A.; Lombardo, M.; Zullo, K.; Johannet, P.M.; Gonzalez, Y.; Scotto, L.; Serrano, X.J.;
Wei, Y.; Duong, J.; et al. Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor
Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib. Clin. Cancer Res. 2017, 23, 3084–3096.
[CrossRef] [PubMed]
150. Liu, Z.; Cai, Y.; Yang, Y.; Li, A.; Bi, R.; Wang, L.; Shen, X.; Wang, W.; Jia, Y.; Yu, B.; et al. Activation of MET
signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic
strategy in diffuse large B-cell lymphoma. J. Pathol. 2018. [CrossRef] [PubMed]
151. Cosenza, M.; Civallero, M.; Marcheselli, L.; Sacchi, S.; Pozzi, S. Ricolinostat, a selective HDAC6 inhibitor,
shows anti-lymphoma cell activity alone and in combination with bendamustine. Apoptosis 2017, 22, 827–840.
[CrossRef] [PubMed]
152. Ray, A.; Das, D.S.; Song, Y.; Hideshima, T.; Tai, Y.-T.; Chauhan, D.; Anderson, K.C. Combination of a novel
HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in
multiple myeloma. Leukemia 2018, 32, 843–846. [CrossRef] [PubMed]
153. Hideshima, T.; Qi, J.; Paranal, R.M.; Tang, W.; Greenberg, E.; West, N.; Colling, M.E.; Estiu, G.; Mazitschek, R.;
Perry, J.A.; et al. Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome
inhibitor resistance in multiple myeloma. Proc. Natl. Acad. Sci. USA 2016, 113, 13162–13167. [CrossRef]
[PubMed]
154. Kawada, J.; Zou, P.; Mazitschek, R.; Bradner, J.E.; Cohen, J.I. Tubacin kills Epstein-Barr virus (EBV)-Burkitt
lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis.
J. Biol. Chem. 2009, 284, 17102–17109. [CrossRef] [PubMed]
155. Butler, K.V.; Kalin, J.; Brochier, C.; Vistoli, G.; Langley, B.; Kozikowski, A.P. Rational design and simple
chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J. Am. Chem. Soc. 2010, 132,
10842–10846. [CrossRef] [PubMed]
156. Simões-Pires, C.A.; Zwick, V.; Cretton, S.; Cuendet, M. Simultaneous Measurement of HDAC1 and HDAC6
Activity in HeLa Cells Using UHPLC-MS. J. Vis. Exp. 2017. [CrossRef] [PubMed]
157. Hideshima, T.; Mazitschek, R.; Santo, L.; Mimura, N.; Gorgun, G.; Richardson, P.G.; Raje, N.; Anderson, K.C.
Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase
inhibitors. Leukemia 2014, 28, 457–460. [CrossRef] [PubMed]
158. Lwin, T.; Zhao, X.; Cheng, F.; Zhang, X.; Huang, A.; Shah, B.; Zhang, Y.; Moscinski, L.C.; Choi, Y.S.;
Kozikowski, A.P.; et al. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in
non-Hodgkin B cell lymphomas. J. Clin. Investig. 2013, 123, 4612–4626. [CrossRef] [PubMed]
159. Raje, N.S.; Bensinger, W.; Cole, C.E.; Lonial, S.; Jagannath, S.; Arce-Lara, C.E.; Valent, J.; Rosko, A.E.;
Harb, W.A.; Sandhu, I.; et al. Ricolinostat (ACY-1215), the First Selective HDAC6 Inhibitor, Combines Safely
with Pomalidomide and Dexamethasone and Shows Promosing Early Results in Relapsed-and-Refractory
Myeloma (ACE-MM-102 Study). Blood 2015, 126, 4228.
160. Niesvizky, R.; Richardson, P.G.; Gabrail, N.Y.; Madan, S.; Yee, A.J.; Quayle, S.N.; Almeciga-Pinto, I.;
Jones, S.S.; Houston, L.; Hayes, D.; et al. ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy
with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results
(ACE-MM-200 Study). Blood 2015, 126, 3040.
161. Yee, A.J.; Voorhees, P.M.; Bensinger, W.; Berdeja, J.G.; Supko, J.G.; Richardson, P.G.; Tamang, D.; Jones, S.S.;
Patrick, G.; Wheeler, C.; et al. Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with
Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple
Myeloma. Blood 2014, 124, 4772.
162. Vogl, D.T.; Raje, N.; Hari, P.; Jones, S.S.; Supko, J.G.; Leone, G.; Wheeler, C.; Orlowski, R.Z.; Richardson, P.G.;
Lonial, S.; et al. Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and
Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). Blood 2014,
124, 4764.
163. Hideshima, T.; Richardson, P.G.; Anderson, K.C. Mechanism of action of proteasome inhibitors and
deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol. Cancer Ther. 2011, 10,
2034–2042. [CrossRef] [PubMed]
164. Garcia-Guerrero, E.; Danhof, S.; Schreder, M.; Pérez-Simón, J.A.; Einsele, H.; Hudecek, M. Upregulation of
CD38 Expression on Multiple Myeloma Cells By the HDAC Inhibitor Ricolinostat Augments the Efficacy of
Daratumumab. Blood 2017, 130, 1803.
Int. J. Mol. Sci. 2018, 19, 2337 26 of 26
165. Vogl, D.T.; Hari, P.N.; Jagannath, S.; Jones, S.S.; Supko, J.G.; Leone, G.; Wheeler, C.; Orlowski, R.Z.;
Richardson, P.G.; Lonial, S. ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results
Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM). Blood 2013, 122, 759.
166. Vorhees, P.; Bensinger, W.I.; Berdeja, J.; Supko, J.G.; Richardson, P.G.; Jones, S.S.; Patrick, G.; Wheeler, C.;
Raje, N. ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, In Combination With Lenalidomide
and Dexamethasone (dex), Is Well Tolerated Without Dose Limiting Toxicity (DLT) In Patients (Pts) With
Multiple Myeloma (MM) At Doses Demonstrating Biologic Activity: Interim Results Of a Phase 1b Trial.
Blood 2013, 122, 3190.
167. Huang, P.; Almeciga-Pinto, I.; Jarpe, M.; van Duzer, J.H.; Mazitschek, R.; Yang, M.; Jones, S.S.; Quayle, S.N.
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models. Oncotarget
2017, 8, 2694–2707. [CrossRef] [PubMed]
168. Bae, J.; Hideshima, T.; Tai, Y.-T.; Song, Y.; Richardson, P.; Raje, N.; Munshi, N.C.; Anderson, K.C. Histone
deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory
cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia 2018. [CrossRef] [PubMed]
169. Jones, S.S. ACY-1215, a First-In-Class Selective Inhibitor of HDAC6, Demonstrates Significant Synergy With
Immunomodulatory Drugs (IMiDs) In Preclinical Models Of Multiple Myeloma (MM). Blood 2013, 122, 1952.
170. Cosenza, M.; Civallero, M.; Sacchi, S.; Pozzi, S. Momelotinib and Citarinostat: Co-Targeting JAK2/STAT3
and HDAC6 in Lymphoid Malignancies, a New Potential Therapeutic Combination. Blood 2017, 130, 5201.
171. Mehrling, T.; Chen, Y. The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next
Level with the First in Class Molecule EDO-S101. Anticancer Agents Med. Chem. 2016, 16, 20–28. [CrossRef]
[PubMed]
172. López-Iglesias, A.A.; San-Segundo, L.; González-Méndez, L.; Hernández-García, S.; Primo, D.; Garayoa, M.;
Hernández, A.B.; Paíno, T.; Mateos, M.-V.; Chen, Y.; et al. The Alkylating Histone Deacetylase Inhibitor
Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological
Malignancies. Blood 2014, 124, 2100.
173. López-Iglesias, A.-A.; Herrero, A.B.; Chesi, M.; San-Segundo, L.; González-Méndez, L.; Hernández-García, S.;
Misiewicz-Krzeminska, I.; Quwaider, D.; Martín-Sánchez, M.; Primo, D.; et al. Preclinical anti-myeloma
activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent
DNA damage induction and impairment of DNA repair. J. Hematol. Oncol. 2017, 10, 127. [CrossRef]
[PubMed]
174. Besse, L.; Kraus, M.; Besse, A.; Bader, J.; Silzle, T.; Mehrling, T.; Driessen, C. The first-in-class alkylating
HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma
through activation of multiple pathways. Blood Cancer J. 2017, 7, e589. [CrossRef] [PubMed]
175. Yan, S.; Xu, K.; Lin, J.; Jayachandran, G.; Wang, B.; Watanabe, Y.; Ge, Q.; Wu, Y.; Guo, D.; Chen, Y.; et al.
Abstract 2741: Synergistic inhibition of tumor growth and overcoming chemo-resistance by simultaneously
targeting key components in DNA damage/repair, epigenetic, and putative cancer stem cell signaling
pathways using novel dual-functional DNA-alkylating/HDAC inhibitor and tumor suppressor gene
nanoparticles in lung cancer. Cancer Res. 2012, 72, 2741. [CrossRef]
176. Shuttleworth, S.J. Abstract 3996: KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting
PI3K-p110β/p110δ and HDAC6 with single-agent and combination activity. Cancer Res. 2016, 76, 3996.
[CrossRef]
177. Dallavalle, S.; Cincinelli, R.; Nannei, R.; Merlini, L.; Morini, G.; Penco, S.; Pisano, C.; Vesci, L.; Barbarino, M.;
Zuco, V.; et al. Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as
histone deacetylase (HDAC) inhibitors. Eur. J. Med. Chem. 2009, 44, 1900–1912. [CrossRef] [PubMed]
178. Zuco, V.; De Cesare, M.; Cincinelli, R.; Nannei, R.; Pisano, C.; Zaffaroni, N.; Zunino, F. Synergistic antitumor
effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo. PLoS ONE 2011, 6, e29085. [CrossRef]
[PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
